| Year |
Citation |
Score |
| 2024 |
Leung KH, Rowe SP, Sadaghiani MS, Leal JP, Mena E, Choyke PL, Du Y, Pomper MG. Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 38423786 DOI: 10.2967/jnumed.123.267048 |
0.31 |
|
| 2023 |
Voter AF, Werner RA, Savas H, Gafita A, Ross AE, Gorin MA, Solnes LB, Pomper MG, Rowe SP, Sheikhbahaei S. A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging. Seminars in Nuclear Medicine. PMID 37980186 DOI: 10.1053/j.semnuclmed.2023.11.001 |
0.367 |
|
| 2023 |
Seifert R, Gafita A, Telli T, Voter A, Herrmann K, Pomper M, Hadaschik B, Rowe SP, Fendler WP. Standardized PSMA-PET Imaging of Advanced Prostate Cancer. Seminars in Nuclear Medicine. PMID 37573199 DOI: 10.1053/j.semnuclmed.2023.07.005 |
0.359 |
|
| 2023 |
Alati S, Singh R, Pomper MG, Rowe SP, Banerjee SR. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer. Seminars in Nuclear Medicine. PMID 37468417 DOI: 10.1053/j.semnuclmed.2023.06.007 |
0.328 |
|
| 2023 |
Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, ... ... Pomper M, et al. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer. European Urology. PMID 37173210 DOI: 10.1016/j.eururo.2023.04.025 |
0.301 |
|
| 2023 |
Rowe SP, Voter AF, Werner RA, Zukotynski KA, Pomper MG, Gorin MA, Solnes LB. Re: "Overcoming Challenges Associated with 18F-DCFPyL PET Imaging in Prostate Cancer". The Canadian Journal of Urology. 30: 11465-11466. PMID 37074744 |
0.329 |
|
| 2023 |
Rowe SP, Voter AF, Werner RA, Zukotynski KA, Pomper MG, Gorin MA, Solnes LB. Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it. The Canadian Journal of Urology. 30: 11432-11437. PMID 36779950 |
0.306 |
|
| 2023 |
Werner RA, Habacha B, Lütje S, Bundschuh L, Kosmala A, Essler M, Derlin T, Higuchi T, Lapa C, Buck AK, Pienta KJ, Lodge MA, Eisenberger MA, Markowski MC, Pomper MG, et al. Lack of repeatability of radiomic features derived from PET scans: Results from a F-DCFPyL test-retest cohort. The Prostate. PMID 36632656 DOI: 10.1002/pros.24483 |
0.319 |
|
| 2022 |
Leung KH, Rowe SP, Leal JP, Ashrafinia S, Sadaghiani MS, Chung HW, Dalaie P, Tulbah R, Yin Y, VanDenBerg R, Werner RA, Pienta KJ, Gorin MA, Du Y, Pomper MG. Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. Ejnmmi Research. 12: 76. PMID 36580220 DOI: 10.1186/s13550-022-00948-1 |
0.32 |
|
| 2022 |
Rowe SP, Salavati A, Werner RA, Pienta KJ, Gorin MA, Pomper MG, Solnes LB. F-Labeled Radiotracers for Prostate-specific Membrane Antigen: Historical Perspective and Future Directions. Pet Clinics. 17: 585-593. PMID 36229102 DOI: 10.1016/j.cpet.2022.07.003 |
0.322 |
|
| 2022 |
Boinapally S, Lisok A, Lofland G, Minn I, Yan Y, Jiang Z, Shin MJ, Merino VF, Zheng L, Brayton C, Pomper MG, Banerjee SR. Hetero-bivalent agents targeting FAP and PSMA. European Journal of Nuclear Medicine and Molecular Imaging. PMID 35965291 DOI: 10.1007/s00259-022-05933-3 |
0.328 |
|
| 2022 |
Voter AF, Werner RA, Pienta KJ, Gorin MA, Pomper MG, Solnes LB, Rowe SP. Piflufolastat F-18 (F-DCFPyL) for PSMA PET imaging in prostate cancer . Expert Review of Anticancer Therapy. PMID 35603510 DOI: 10.1080/14737140.2022.2081155 |
0.346 |
|
| 2022 |
Werner RA, Habacha B, Lütje S, Bundschuh L, Higuchi T, Hartrampf P, Serfling SE, Derlin T, Lapa C, Buck AK, Essler M, Pienta KJ, Eisenberger MA, Markowski MC, Shinehouse L, ... ... Pomper MG, et al. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL. Molecular Imaging. 2022: 7056983. PMID 35283693 DOI: 10.1155/2022/7056983 |
0.33 |
|
| 2022 |
Rowe SP, Buck A, Bundschuh RA, Lapa C, Serfling SE, Derlin T, Higuchi T, Gorin MA, Pomper MG, Werner RA. [18F]DCFPyL PET/CT for Imaging of Prostate Cancer. Nuklearmedizin. Nuclear Medicine. PMID 35030637 DOI: 10.1055/a-1659-0010 |
0.312 |
|
| 2021 |
Cheng MHY, Overchuk M, Rajora MA, Lou JWH, Chen Y, Pomper MG, Chen J, Zheng G. Targeted Theranostic In/Lu-Nanotexaphyrin for SPECT Imaging and Photodynamic Therapy. Molecular Pharmaceutics. PMID 34965727 DOI: 10.1021/acs.molpharmaceut.1c00819 |
0.339 |
|
| 2021 |
Zhang J, Rakhimbekova A, Duan X, Yin Q, Foss CA, Fan Y, Xu Y, Li X, Cai X, Kutil Z, Wang P, Yang Z, Zhang N, Pomper MG, Wang Y, et al. A prostate-specific membrane antigen activated molecular rotor for real-time fluorescence imaging. Nature Communications. 12: 5460. PMID 34526506 DOI: 10.1038/s41467-021-25746-6 |
0.305 |
|
| 2021 |
Lesniak WG, Wu Y, Kang J, Boinapally S, Ray Banerjee S, Lisok A, Jablonska A, Boctor EM, Pomper MG. Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer. Nanoscale. PMID 33978042 DOI: 10.1039/d1nr00669j |
0.335 |
|
| 2021 |
Khatri W, Chung HW, Werner RA, Leal JP, Pienta KJ, Lodge MA, Gorin MA, Pomper MG, Rowe SP. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer. Diagnostics (Basel, Switzerland). 11. PMID 33917238 DOI: 10.3390/diagnostics11040665 |
0.31 |
|
| 2021 |
Boinapally S, Ahn HH, Cheng B, Brummet M, Nam H, Gabrielson KL, Banerjee SR, Minn I, Pomper MG. A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile. Scientific Reports. 11: 7114. PMID 33782486 DOI: 10.1038/s41598-021-86551-1 |
0.332 |
|
| 2021 |
Slania SL, Das D, Lisok A, Du Y, Jiang Z, Mease RC, Rowe SP, Nimmagadda S, Yang X, Pomper MG. Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. Journal of Medicinal Chemistry. PMID 33730493 DOI: 10.1021/acs.jmedchem.0c02171 |
0.338 |
|
| 2020 |
Tong L, Zhao Q, Datan E, Lin GQ, Minn I, Pomper MG, Yu B, Romo D, He QL, Liu JO. Triptolide: reflections on two decades of research and prospects for the future. Natural Product Reports. PMID 33146205 DOI: 10.1039/d0np00054j |
0.754 |
|
| 2020 |
Datan E, Minn I, Xu P, He QL, Ahn HH, Yu B, Pomper MG, Liu JO. A Glucose-Triptolide Conjugate Selectively Targets Cancer Cells under Hypoxia. Iscience. 23: 101536. PMID 33083765 DOI: 10.1016/J.Isci.2020.101536 |
0.792 |
|
| 2020 |
Santhanam P, Russell J, Rooper LM, Ladenson PW, Pomper MG, Rowe SP. The prostate-specific membrane antigen (PSMA)-targeted radiotracer F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. Medical Oncology (Northwood, London, England). 37: 98. PMID 33034761 DOI: 10.1007/s12032-020-01427-0 |
0.316 |
|
| 2020 |
Novakova Z, Belousova N, Foss CA, Havlinova B, Gresova M, Das G, Lisok A, Prada A, Barinkova M, Hubalek M, Pomper MG, Barinka C. Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization. International Journal of Molecular Sciences. 21. PMID 32932591 DOI: 10.3390/Ijms21186672 |
0.381 |
|
| 2020 |
Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, Larson SM, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, et al. Meeting report from the prostate cancer foundation PSMA theranostics state of the science meeting. The Prostate. PMID 32865839 DOI: 10.1002/Pros.24056 |
0.37 |
|
| 2020 |
Werner RA, Derlin T, Rowe SP, Bundschuh L, Sheikh GT, Pomper MG, Schulz S, Higuchi T, Buck AK, Bengel FM, Bundschuh RA, Lapa C. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 32859702 DOI: 10.2967/Jnumed.120.245464 |
0.319 |
|
| 2020 |
Huang CT, Guo X, Bařinka C, Lupold SE, Pomper MG, Gabrielson K, Raman V, Artemov D, Hapuarachchige S. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Molecular Pharmaceutics. PMID 32803984 DOI: 10.1021/Acs.Molpharmaceut.0C00457 |
0.418 |
|
| 2020 |
Gaur S, Mena E, Harmon SA, Lindenberg ML, Adler S, Ton AT, Shih JH, Mehralivand S, Merino MJ, Wood BJ, Pinto PA, Mease RC, Pomper MG, Choyke PL, Turkbey B. Prospective Evaluation of F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. Ajr. American Journal of Roentgenology. 1-8. PMID 32755168 DOI: 10.2214/Ajr.19.22042 |
0.431 |
|
| 2020 |
Cho SY, Rowe SP, Jain SK, Schon LC, Yung RC, Nayfeh TA, Bingham CO, Foss CA, Nimmagadda S, Pomper MG. Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [I]FIAU PET/CT. Molecular Imaging. 19: 1536012120936876. PMID 32598214 DOI: 10.1177/1536012120936876 |
0.313 |
|
| 2020 |
Du Y, Minn I, Foss C, Lesniak WG, Hu F, Dannals RF, Pomper MG, Horti AG. PET imaging of soluble epoxide hydrolase in non-human primate brain with [F]FNDP. Ejnmmi Research. 10: 67. PMID 32572592 DOI: 10.1186/S13550-020-00657-7 |
0.365 |
|
| 2020 |
Cao Q, Lu X, Azad BB, Pomper M, Smith M, He J, Pi L, Ren B, Ying Z, Sichani BS, Morris M, Dilsizian V. -4-[F]fluoro-L-proline Molecular Imaging Experimental Liver Fibrosis. Frontiers in Molecular Biosciences. 7: 90. PMID 32500081 DOI: 10.3389/Fmolb.2020.00090 |
0.329 |
|
| 2020 |
Hasan H, Deek MP, Phillips R, Hobbs RF, Malek R, Radwan N, Kiess AP, Dipasquale S, Huang J, Caldwell T, Leitzel J, Wendler D, Wang H, Thompson E, Powell J, ... ... Pomper MG, et al. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS). Bmc Cancer. 20: 492. PMID 32487038 DOI: 10.1186/S12885-020-07000-2 |
0.343 |
|
| 2020 |
Rowe SP, Gorin MA, Pomper MG. Prostate-specific membrane antigen (PSMA) imaging: the past is prologue and the future is scintillating. Translational Andrology and Urology. 9: 840-842. PMID 32420196 DOI: 10.21037/Tau.2020.01.27 |
0.399 |
|
| 2020 |
Rowe SP, Johnson GB, Pomper MG, Gorin MA, Behr SC. Recent updates and developments in PET imaging of prostate cancer. Abdominal Radiology (New York). PMID 32417934 DOI: 10.1007/S00261-020-02570-Y |
0.478 |
|
| 2020 |
Hrinivich WT, Phillips R, Da Silva AJ, Radwan N, Gorin MA, Rowe SP, Pienta KJ, Pomper MG, Wong J, Tran PT, Kang-Hsin Wang K. Online Prostate-Specific Membrane Antigen and Positron Emission Tomography-Guided Radiation Therapy for Oligometastatic Prostate Cancer. Advances in Radiation Oncology. 5: 260-268. PMID 32280826 DOI: 10.1016/J.Adro.2019.10.006 |
0.409 |
|
| 2020 |
Markowski MC, Sedhom R, Fu W, Gray JCR, Eisenberger MA, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. PSA and PSA Doubling Time Predict Findings on F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32250727 DOI: 10.1097/Ju.0000000000001064 |
0.429 |
|
| 2020 |
Jadvar H, Ballas LK, Choyke PL, Fanti S, Gulley JL, Herrmann K, Hope TA, Klitzke AK, Oldan JD, Pomper MG, Rowe SP, Subramaniam RM, Taneja SS, Vargas HA, Ahuja S. Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 61: 552-562. PMID 32238495 DOI: 10.2967/Jnumed.119.240929 |
0.402 |
|
| 2020 |
Leung KH, Marashdeh W, Wray R, Ashrafinia S, Pomper MG, Rahmim A, Jha AK. A physics-guided modular deep-learning based automated framework for tumor segmentation in PET. Physics in Medicine and Biology. PMID 32235059 DOI: 10.1088/1361-6560/Ab8535 |
0.368 |
|
| 2020 |
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, ... ... Pomper MG, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. Jama Oncology. PMID 32215577 DOI: 10.1001/Jamaoncol.2020.0147 |
0.359 |
|
| 2020 |
Duan X, Liu F, Kwon H, Byun Y, Minn I, Cai X, Zhang J, Pomper MG, Yang Z, Xi Z, Yang X. (S)-3-(Carboxyformamido)-2-(3-(carboxymethyl)ureido)propanoic Acid as A Novel PSMA Targeting Scaffold for Prostate Cancer Imaging. Journal of Medicinal Chemistry. PMID 32207938 DOI: 10.1021/Acs.Jmedchem.9B02031 |
0.418 |
|
| 2020 |
Shen CJ, Minn I, Hobbs RF, Chen Y, Josefsson A, Brummet M, Banerjee SR, Brayton CF, Mease RC, Pomper MG, Kiess AP. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. Theranostics. 10: 2888-2896. PMID 32194842 DOI: 10.7150/Thno.38882 |
0.407 |
|
| 2020 |
Kim K, Kwon H, Bařinka C, Motlova L, Nam S, Choi D, Ha H, Nam H, Son SH, Minn I, Pomper MG, Yang X, Kutil Z, Byun Y. Novel β- and γ-amino acid derived inhibitors of prostate-specific membrane antigen. Journal of Medicinal Chemistry. PMID 32097010 DOI: 10.1021/Acs.Jmedchem.9B02022 |
0.341 |
|
| 2020 |
Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, Rosenkrantz AB, Verma S, Margolis DJ, Froemming A, Oto A, Purysko A, Milowsky MI, Schlemmer HP, Eiber M, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902757. PMID 31940221 DOI: 10.1200/Jco.19.02757 |
0.424 |
|
| 2020 |
Solnes L, Werner R, Jones KM, Sadaghiani MS, Bailey CR, Lapa C, Pomper MG, Rowe SP. Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31924727 DOI: 10.2967/Jnumed.118.220665 |
0.343 |
|
| 2020 |
Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP. F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. Theranostics. 10: 1-16. PMID 31903102 DOI: 10.7150/Thno.37894 |
0.45 |
|
| 2020 |
Nakajima EC, Leal JP, Fu W, Wang H, Chaft JE, Hellmann MD, Pomper M, Forde PM. CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 38: 9031-9031. DOI: 10.1200/Jco.2020.38.15_Suppl.9031 |
0.363 |
|
| 2019 |
Yin Y, Paller CJ, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. World Journal of Nuclear Medicine. 18: 424-427. PMID 31933562 DOI: 10.4103/Wjnm.Wjnm_50_18 |
0.457 |
|
| 2019 |
Torga G, Yin Y, Pomper MG, Pienta KJ, Gorin MA, Rowe SP. Uptake of prostate-specific membrane antigen-targeted F-DCFPyL in avascular necrosis of the femoral head. World Journal of Nuclear Medicine. 18: 416-419. PMID 31933560 DOI: 10.4103/Wjnm.Wjnm_106_18 |
0.457 |
|
| 2019 |
Hapuarachchige S, Huang CT, Donnelly MC, Bařinka C, Lupold SE, Pomper MG, Artemov D. Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Molecular Pharmaceutics. PMID 31840521 DOI: 10.1021/Acs.Molpharmaceut.9B00788 |
0.374 |
|
| 2019 |
Werner RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP, Lodge MA, Bundschuh RA. Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake". Molecular Imaging and Biology. PMID 31832870 DOI: 10.1007/S11307-019-01452-0 |
0.385 |
|
| 2019 |
Overchuk M, Damen MPF, Harmatys KM, Pomper MG, Chen J, Zheng G. Long-Circulating Prostate-Specific Membrane Antigen-Targeted NIR Phototheranostic Agent. Photochemistry and Photobiology. PMID 31742696 DOI: 10.1111/Php.13181 |
0.437 |
|
| 2019 |
Narayan A, Yan Y, Lisok A, Brummet M, Pomper MG, Lesniak WG, Dannals RF, Merino VF, Azad BB. A side-by-side evaluation of [F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography. Oncotarget. 10: 5731-5744. PMID 31645896 DOI: 10.18632/Oncotarget.27184 |
0.359 |
|
| 2019 |
Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, Lam S, Boehm MA, Ruiz C, Farrell MR, Moreno A, Galal Faress IM, Andersen N, Lin JY, Moaddel R, ... ... Pomper MG, et al. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications. 10: 4627. PMID 31604917 DOI: 10.1038/S41467-019-12236-Z |
0.337 |
|
| 2019 |
Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, Buck AK, Pomper MG, Rowe SP, Lapa C. CXCR4-Directed Imaging in Solid Tumors. Frontiers in Oncology. 9: 770. PMID 31475113 DOI: 10.3389/Fonc.2019.00770 |
0.389 |
|
| 2019 |
Rowe SP, Li X, Trock BJ, Werner RA, Frey SM, DiGianvittorio M, Bleiler K, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG. Prospective Comparison of PET Imaging with PSMA-targeted F-DCFPyL versus NaF for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31451492 DOI: 10.2967/Jnumed.119.227793 |
0.406 |
|
| 2019 |
Banerjee SR, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs RF, Pomper MG. Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. European Journal of Nuclear Medicine and Molecular Imaging. PMID 31399803 DOI: 10.1007/S00259-019-04434-0 |
0.385 |
|
| 2019 |
Batra JS, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications? Translational Andrology and Urology. 8: S263-S264. PMID 31392140 DOI: 10.21037/Tau.2019.03.13 |
0.385 |
|
| 2019 |
Rowe SP, Solnes LB, Yin Y, Kitchen G, Lodge MA, Karakatsanis NA, Rahmim A, Pomper MG, Leal JP. Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data. Journal of Digital Imaging. PMID 31388864 DOI: 10.1007/S10278-019-00255-7 |
0.346 |
|
| 2019 |
Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA. A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. The Prostate. PMID 31361358 DOI: 10.1002/Pros.23883 |
0.406 |
|
| 2019 |
Werner RA, Thackeray JT, Pomper MG, Bengel FM, Gorin MA, Derlin T, Rowe SP. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. Journal of Clinical Medicine. 8. PMID 31331016 DOI: 10.3390/Jcm8071060 |
0.439 |
|
| 2019 |
Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, Brummet M, Rowe SP, Sysa-Shah P, Du Y, Levitsky HI, Pomper MG. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Science Advances. 5: eaaw5096. PMID 31281894 DOI: 10.1126/Sciadv.Aaw5096 |
0.358 |
|
| 2019 |
Ray Banerjee S, Minn IL, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess A, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31253744 DOI: 10.2967/Jnumed.119.229393 |
0.341 |
|
| 2019 |
Breun M, Monoranu CM, Kessler AF, Matthies C, Löhr M, Hagemann C, Schirbel A, Rowe SP, Pomper MG, Buck AK, Wester HJ, Ernestus RI, Lapa C. [Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas. Frontiers in Oncology. 9: 503. PMID 31245296 DOI: 10.3389/Fonc.2019.00503 |
0.336 |
|
| 2019 |
Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine. 49: 255-270. PMID 31227049 DOI: 10.1053/J.Semnuclmed.2019.02.006 |
0.46 |
|
| 2019 |
Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA. Prospective Evaluation of PSMA-Targeted F-DCFPyL PET/CT in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31201249 DOI: 10.2967/Jnumed.119.226514 |
0.42 |
|
| 2019 |
Lesniak WG, Mease RC, Chatterjee S, Kumar D, Lisok A, Wharram B, Kalagadda VR, Emens LA, Pomper MG, Nimmagadda S. Development of [F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. Molecular Imaging. 18: 1536012119852189. PMID 31187691 DOI: 10.1177/1536012119852189 |
0.328 |
|
| 2019 |
Meyer AR, Carducci MA, Denmeade SR, Markowski MC, Pomper MG, Pierorazio PM, Allaf ME, Rowe SP, Gorin MA. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted F-DCFPyL PET/CT. Annals of Nuclear Medicine. PMID 31147927 DOI: 10.1007/S12149-019-01371-8 |
0.327 |
|
| 2019 |
Werner RA, Chen X, Lapa C, Koshino K, Rowe SP, Pomper MG, Javadi MS, Higuchi T. The next era of renal radionuclide imaging: novel PET radiotracers. European Journal of Nuclear Medicine and Molecular Imaging. PMID 31144061 DOI: 10.1007/S00259-019-04359-8 |
0.365 |
|
| 2019 |
Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31140110 DOI: 10.1007/S11307-019-01375-W |
0.428 |
|
| 2019 |
Werner RA, Savoie B, Javadi MS, Pomper MG, Higuchi T, Lapa C, Rowe SP. From the Reading Room to the Courtroom-The Use of Molecular Radionuclide Imaging in Criminal Trials. Journal of the American College of Radiology : Jacr. PMID 31132333 DOI: 10.1016/J.Jacr.2019.05.001 |
0.341 |
|
| 2019 |
Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31115751 DOI: 10.1007/S11307-019-01376-9 |
0.449 |
|
| 2019 |
Lesniak WG, Boinapally S, Banerjee SR, Behnam Azad B, Foss CA, Shen C, Lisok A, Wharram B, Nimmagadda S, Pomper MG. Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. Molecular Pharmaceutics. PMID 31002252 DOI: 10.1021/Acs.Molpharmaceut.9B00181 |
0.413 |
|
| 2019 |
Paranjpe MD, Chen X, Liu M, Paranjpe I, Leal JP, Wang R, Pomper MG, Wong DF, Benzinger TLS, Zhou Y. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study. Neuroimage. Clinical. 22: 101795. PMID 30991617 DOI: 10.1016/J.Nicl.2019.101795 |
0.324 |
|
| 2019 |
Ngen EJ, Behnam Azad B, Boinapally S, Lisok A, Brummet M, Jacob D, Pomper MG, Banerjee SR. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. Molecular Pharmaceutics. PMID 30912947 DOI: 10.1021/Acs.Molpharmaceut.9B00036 |
0.438 |
|
| 2019 |
Coughlin JM, Horti AG, Pomper MG. Opportunities in precision psychiatry using PET neuroimaging in psychosis. Neurobiology of Disease. PMID 30904669 DOI: 10.1016/J.Nbd.2019.03.016 |
0.361 |
|
| 2019 |
Copeland BT, Shallal H, Shen C, Pienta KJ, Foss CA, Pomper MG. Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 30805886 DOI: 10.1007/S11307-019-01318-5 |
0.412 |
|
| 2019 |
Yu J, Li N, Li J, Lu M, Leal JP, Tan H, Su H, Fan Y, Zhang Y, Zhao W, Zhu H, Pomper MG, Zhou Y, Yang Z. The Correlation Between [Ga]DOTATATE PET/CT and Cell Proliferation in Patients With GEP-NENs. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 30796708 DOI: 10.1007/S11307-019-01328-3 |
0.319 |
|
| 2019 |
Werner RA, Bundschuh R, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP. Introduction of Novel Structured Reporting Systems for PET Radiotracers with Potential Theranostic Applications. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30796171 DOI: 10.2967/Jnumed.118.223537 |
0.385 |
|
| 2019 |
Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine. PMID 30789396 DOI: 10.1097/Rlu.0000000000002489 |
0.395 |
|
| 2019 |
Werner RA, Ordonez AA, Sanchez-Bautista J, Marcus C, Lapa C, Rowe SP, Pomper MG, Leal JP, Lodge MA, Javadi MS, Jain SK, Higuchi T. Novel Functional Renal PET Imaging With 18F-FDS in Human Subjects. Clinical Nuclear Medicine. PMID 30762825 DOI: 10.1097/Rlu.0000000000002494 |
0.325 |
|
| 2019 |
Reyes DK, Demehri S, Werner RA, Pomper MG, Gorin MA, Rowe SP, Pienta KJ. PSMA-targeted [F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urology Case Reports. 23: 72-74. PMID 30705827 DOI: 10.1016/J.Eucr.2019.01.007 |
0.376 |
|
| 2019 |
Rowe SP, Gorin MA, Pomper MG. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications. Annual Review of Medicine. 70: 461-477. PMID 30691373 DOI: 10.1146/Annurev-Med-062117-073027 |
0.487 |
|
| 2019 |
Horti AG, Naik R, Foss CA, Minn I, Misheneva V, Du Y, Wang Y, Mathews WB, Wu Y, Hall A, LaCourse C, Ahn HH, Nam H, Lesniak WG, Valentine H, ... ... Pomper MG, et al. PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proceedings of the National Academy of Sciences of the United States of America. PMID 30635412 DOI: 10.1073/Pnas.1812155116 |
0.328 |
|
| 2019 |
Coughlin J, Du Y, Rowe S, Horti A, Pomper M. 14.3 OPPORTUNITIES IN PRECISION PSYCHIATRY USING PET-BASED NEUROIMAGING Schizophrenia Bulletin. 45: S111-S112. DOI: 10.1093/Schbul/Sbz022.056 |
0.315 |
|
| 2019 |
Phillips R, Lim S, Shi W, Antonarakis E, Rowe S, Gorin M, Deville C, Greco S, Denmeade S, Paller C, DeWeese T, Song D, Wang H, Carducci M, Pienta K, ... Pomper M, et al. Primary Outcomes of a Phase II Randomized Trial of Observation Versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) International Journal of Radiation Oncology*Biology*Physics. 105: 681. DOI: 10.1016/J.Ijrobp.2019.08.031 |
0.316 |
|
| 2018 |
Harmon SA, Mena E, Shih JH, Adler S, McKinney Y, Bergvall E, Mehralivand S, Sowalsky AG, Couvillon A, Madan RA, Gulley JL, Eary J, Mease RC, Pomper MG, Dahut WL, et al. A comparison of prostate cancer bone metastases on F-Sodium Fluoride and Prostate Specific Membrane Antigen (F-PSMA) PET/CT: Discordant uptake in the same lesion. Oncotarget. 9: 37676-37688. PMID 30701023 DOI: 10.18632/Oncotarget.26481 |
0.411 |
|
| 2018 |
Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics. 8: 6088-6100. PMID 30613284 DOI: 10.7150/Thno.30357 |
0.36 |
|
| 2018 |
Jiang S, Eberhart CG, Lim M, Heo HY, Zhang Y, Blair L, Wen Z, Holdhoff M, Lin D, Huang P, Qin H, Quiñones-Hinojosa A, Weingart J, Barker P, Pomper MG, et al. Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30366937 DOI: 10.1158/1078-0432.Ccr-18-1233 |
0.318 |
|
| 2018 |
Harmatys K, Overchuk M, Chen J, Ding L, Chen Y, Pomper MG, Zheng G. Tuning Pharmacokinetics to Improve Tumor Accumulation of a PSMA-Targeted Phototheranostic Agent. Bioconjugate Chemistry. PMID 30350576 DOI: 10.1021/Acs.Bioconjchem.8B00636 |
0.404 |
|
| 2018 |
Lesniak WG, Chu C, Jablonska A, Du Y, Pomper MG, Walczak P, Janowski M. PET imaging of intra-arterial Zr bevacizumab in mice with and without osmotic opening of the blood-brain barrier: distinct advantage of intra-arterial delivery. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30315146 DOI: 10.2967/Jnumed.118.218792 |
0.34 |
|
| 2018 |
Salas Fragomeni RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas. Clinical Nuclear Medicine. PMID 30247210 DOI: 10.1097/Rlu.0000000000002280 |
0.459 |
|
| 2018 |
Ray Banerejee S, Kumar V, Lisok A, Plyku D, Nováková Z, Wharram B, Brummet M, Barinka C, Hobbs RF, Pomper MG. Evaluation of In-DOTA-5D3, a Surrogate SPECT Imaging Agent for Radioimmunotherapy of Prostate-Specific Membrane Antigen. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30237212 DOI: 10.2967/Jnumed.118.214403 |
0.398 |
|
| 2018 |
Yin Y, Campbell SP, Markowski MC, Pierorazio PM, Pomper MG, Allaf ME, Rowe SP, Gorin MA. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [F]DCFPyL PET/CT. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 30218388 DOI: 10.1007/S11307-018-1271-2 |
0.376 |
|
| 2018 |
Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on F-DCFPyL PET/CT Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30190304 DOI: 10.2967/Jnumed.118.217588 |
0.373 |
|
| 2018 |
Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, Gorin MA, Rowe SP. Follow-Up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30190303 DOI: 10.2967/Jnumed.118.217653 |
0.313 |
|
| 2018 |
Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Annals of Nuclear Medicine. PMID 30109562 DOI: 10.1007/S12149-018-1291-7 |
0.438 |
|
| 2018 |
De Silva RA, Kumar D, Lisok A, Chatterjee S, Wharram B, Rao KV, Mease RC, Dannals RF, Pomper MG, Nimmagadda S. A peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer. Molecular Pharmaceutics. PMID 30037229 DOI: 10.1021/Acs.Molpharmaceut.8B00399 |
0.333 |
|
| 2018 |
Wang Z, Jacobson O, Tian R, Mease RC, Kiesewetter D, Niu G, Pomper MG, Chen X. Radioligand Therapy of Prostate Cancer with a Long-lasting PSMA Targeting Agent 90Y-DOTA-EB-MCG. Bioconjugate Chemistry. PMID 29865797 DOI: 10.1021/Acs.Bioconjchem.8B00292 |
0.427 |
|
| 2018 |
Vaidyanathan G, Kang CM, McDougald D, Minn I, Brummet M, Pomper MG, Zalutsky MR. Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nuclear Medicine and Biology. 62: 18-30. PMID 29803076 DOI: 10.1016/J.Nucmedbio.2018.05.002 |
0.37 |
|
| 2018 |
Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. The Prostate. PMID 29717499 DOI: 10.1002/Pros.23642 |
0.358 |
|
| 2018 |
Foss CA, Plyku D, Ordonez AA, Sanchez-Bautista J, Rosenthal HB, Minn IL, Lodge MA, Pomper MG, Sgouros G, Jain SK. Biodistribution and Radiation Dosimetry of I-iodo-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29700124 DOI: 10.2967/Jnumed.117.207431 |
0.318 |
|
| 2018 |
Pomper MG, Lee S. Molecularly Targeted MR Imaging Agent in Liver Fibrosis: High Sensitivity and Low Gadolinium Mean High Translational Potential. Radiology. 287: 590-591. PMID 29668411 DOI: 10.1148/Radiol.2018180084 |
0.322 |
|
| 2018 |
Zhang HK, Chen Y, Kang J, Lisok A, Minn I, Pomper MG, Boctor EM. Prostate Specific Membrane Antigen (PSMA)-Targeted Photoacoustic Imaging of Prostate Cancer In Vivo. Journal of Biophotonics. e201800021. PMID 29653029 DOI: 10.1002/Jbio.201800021 |
0.473 |
|
| 2018 |
Werner RA, Andree C, Javadi MS, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP, Pienta KJ. A Voice From the Past: Re-Discovering the Virchow Node with PSMA-TargetedF-DCFPyL PET Imaging. Urology. PMID 29626569 DOI: 10.1016/J.Urology.2018.03.030 |
0.335 |
|
| 2018 |
Harmon SA, Bergvall E, Mena E, Shih JH, Adler S, McKinney Y, Mehralivand S, Citrin DE, Couvillon A, Madan R, Gulley J, Mease RC, Jacobs PM, Pomper MG, Turkbey B, et al. A Prospective Comparison ofF-Sodium Fluoride PET/CT and PSMA-targetedF-DCFBC PET/CT in Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29602821 DOI: 10.2967/Jnumed.117.207373 |
0.4 |
|
| 2018 |
Werner RA, Solnes L, Javadi M, Weich A, Gorin M, Pienta K, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. SSTR-RADS Version 1.0 as a Reporting System for SSTR-PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29572257 DOI: 10.2967/Jnumed.117.206631 |
0.37 |
|
| 2018 |
Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes L, Kiess A, Allaf ME, Pomper M, Gorin MA, Rowe SP. Imaging of Non-Prostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29545375 DOI: 10.2967/Jnumed.117.203570 |
0.424 |
|
| 2018 |
Shenderov E, Gorin MA, Kim S, Johnson PT, Allaf ME, Partin AW, Pomper MG, Antonarakis ES, Pienta KJ, Rowe SP. Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation. Urology Case Reports. 17: 22-25. PMID 29541580 DOI: 10.1016/J.Eucr.2017.12.011 |
0.468 |
|
| 2018 |
Ray Banerjee S, Song X, Yang X, Minn I, Lisok A, Chen Y, Pomper MG, C M van Zijl P, McMahon M, Chen J. Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 29508450 DOI: 10.1002/Chem.201800882 |
0.419 |
|
| 2018 |
Coughlin JM, Slania S, Du Y, Rosenthal HB, Lesniak WG, Minn I, Smith GS, Dannals RF, Kuwabara H, Wong DF, Wang Y, Horti AG, Pomper MG.
F-XTRA PET for enhanced imaging of the extrathalamic α4β2 nicotinic acetylcholine receptor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29496987 DOI: 10.2967/Jnumed.117.205492 |
0.336 |
|
| 2018 |
Plyku D, Mena E, Rowe SP, Lodge MA, Szabo Z, Cho SY, Pomper MG, Sgouros G, Hobbs RF. Combined model-based and patient-specific dosimetry forF-DCFPyL, a PSMA-targeted PET agent. European Journal of Nuclear Medicine and Molecular Imaging. PMID 29460025 DOI: 10.1007/S00259-018-3939-X |
0.454 |
|
| 2018 |
Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, Pacher P, Schindler TH. Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach. Jacc. Cardiovascular Imaging. 11: 320-332. PMID 29413441 DOI: 10.1016/J.Jcmg.2017.11.019 |
0.326 |
|
| 2018 |
Rowe SP, Pomper MG, Gorin MA. Molecular Imaging of Prostate Cancer: Choosing the Right Agent. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29371403 DOI: 10.2967/Jnumed.117.206318 |
0.417 |
|
| 2018 |
Zukotynski KA, Valliant J, Bénard F, Rowe SP, Kim CK, Pomper MG, Cho SY. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations. Clinical Nuclear Medicine. PMID 29356735 DOI: 10.1097/Rlu.0000000000001966 |
0.418 |
|
| 2018 |
Phillips RM, Gorin MA, Rowe SP, Pomper MG, Pienta KJ, Ross AE, Tran PT. Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urology Case Reports. 16: 86-88. PMID 29226093 DOI: 10.1016/J.Eucr.2017.11.021 |
0.388 |
|
| 2018 |
Kulkarni HR, Langbein T, Atay C, Singh A, Schuchardt C, Lehmann C, Pomper M, Pienta KJ, Baum RP. Abstract CT015: Safety and long-term efficacy of radioligand therapy using Lu-177 labeled PSMA ligands in metastatic prostate cancer: A single center experience over 5 years Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct015 |
0.42 |
|
| 2018 |
Coughlin J, Notter T, Du Y, Pomper M, Sawa A, Meyer U. 6.1 STUDY OF ALTERED NEUROIMMUNITY IN PSYCHOSIS USING PET-BASED IMAGING OF THE TRANSLOCATOR PROTEIN 18 KDA: PROMISES, PITFALLS, AND FUTURE DIRECTIONS Schizophrenia Bulletin. 44: S8-S8. DOI: 10.1093/Schbul/Sby014.018 |
0.37 |
|
| 2018 |
Tran P, Radwan N, Phillips R, Ross A, Rowe S, Gorin M, Antonarakis E, DeVille C, Greco S, Denmeade S, Paller C, Song D, Diehn M, Wang H, Carducci M, ... ... Pomper M, et al. OC-0505: Interim results of a randomized trial of observation versus SABR for oligometastatic prostate cancer Radiotherapy and Oncology. 127: S261. DOI: 10.1016/S0167-8140(18)30815-6 |
0.349 |
|
| 2018 |
Horn A, Smith C, Harmon S, Ning H, Pomper M, Schott E, Cooley-Zgela T, Choyke P, Mena Gonzalez E, Turkbey B, Citrin D, Lindenberg L, Rowe L. Evaluating Patterns of Prostate Cancer Recurrence on 18F-DCFBC PET/CT Imaging in Relationship to RTOG Consensus Post-prostatectomy and Pelvic Lymph Node Treatment Volumes International Journal of Radiation Oncology*Biology*Physics. 102: e118. DOI: 10.1016/J.Ijrobp.2018.07.319 |
0.397 |
|
| 2018 |
Phillips R, Radwan N, Ross A, Rowe S, Gorin M, Antonarakis E, Deville C, Greco S, Denmeade S, Paller C, Song D, Wang H, Carudcci M, Pienta K, Pomper M, et al. Interim Results of a Randomized Trial of Observation Versus SABR for Castration-Sensitive Oligometastatic Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e134-e135. DOI: 10.1016/J.Ijrobp.2018.07.257 |
0.352 |
|
| 2018 |
Phillips R, Da Silva A, Radwan N, Gorin M, Rowe S, Deville C, Song D, Greco S, Pienta K, Pomper M, DeWeese T, Wong J, Tran P, Wang K. PSMA-Directed Biologically-Guided Radiation Therapy of Castration-Sensitive Oligometastatic Prostate Cancer Patients International Journal of Radiation Oncology*Biology*Physics. 102: S152. DOI: 10.1016/J.Ijrobp.2018.06.367 |
0.353 |
|
| 2018 |
Alon L, Kraitchman DL, Schär M, Cortez A, Yadav NN, Krimins R, Johnston PV, McMahon MT, Zijl PCMv, Nimmagadda S, Pomper MG, Bulte JWM, Gilad AA. Molecular Imaging of CXCL12 Promoter-driven HSV1-TK Reporter Gene Expression Biotechnology and Bioprocess Engineering. 23: 208-217. DOI: 10.1007/S12257-018-0006-1 |
0.337 |
|
| 2017 |
Liu G, Ray Banerjee S, Yang X, Yadav N, Lisok A, Jablonska A, Xu J, Li Y, Pomper MG, van Zijl P. A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen. Nature Biomedical Engineering. 1: 977-982. PMID 29456877 DOI: 10.1038/S41551-017-0168-8 |
0.424 |
|
| 2017 |
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, ... ... Pomper MG, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706. PMID 29208398 DOI: 10.1016/S1470-2045(17)30698-8 |
0.309 |
|
| 2017 |
Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, ... Pomper MG, et al. Correction: Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. The Journal of Experimental Medicine. PMID 29183990 DOI: 10.1084/Jem.2017105211212017C |
0.306 |
|
| 2017 |
Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, ... Pomper MG, et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. The Journal of Experimental Medicine. PMID 29141866 DOI: 10.1084/Jem.20171052 |
0.411 |
|
| 2017 |
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies. European Urology. PMID 29132714 DOI: 10.1016/J.Eururo.2017.10.027 |
0.463 |
|
| 2017 |
Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA. Low levels of PSMA expression limit the utility of (18)F-DCFPyL PET/CT for imaging urothelial carcinoma. Annals of Nuclear Medicine. PMID 29067547 DOI: 10.1007/S12149-017-1216-X |
0.349 |
|
| 2017 |
Nimmagadda S, Pullambhatla M, Chen Y, Parsana P, Lisok A, Chatterjee S, Mease R, Rowe SP, Lupold SE, Pienta KJ, Pomper MG. Low level endogenous prostate-specific membrane antigen (PSMA) expression in non-prostatic tumor xenografts is sufficient for in vivo tumor targeting and imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29025989 DOI: 10.2967/Jnumed.117.191221 |
0.413 |
|
| 2017 |
Lee S, Jung S, Koo H, Na JH, Yoon HY, Shim MK, Park J, Kim JH, Lee S, Pomper MG, Kwon IC, Ahn CH, Kim K. Nano-sized metabolic precursors for heterogeneous tumor-targeting strategy using bioorthogonal click chemistry in vivo. Biomaterials. 148: 1-15. PMID 28957709 DOI: 10.1016/J.Biomaterials.2017.09.025 |
0.324 |
|
| 2017 |
Mena E, Lindenberg ML, Shih JH, Adler S, Harmon S, Bergvall E, Citrin D, Dahut W, Ton AT, McKinney Y, Weaver J, Eclarinal P, Forest A, Afari G, Bhattacharyya S, ... ... Pomper MG, et al. Clinical impact of PSMA-based (18)F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28894899 DOI: 10.1007/S00259-017-3818-X |
0.427 |
|
| 2017 |
Rowe S, Pienta K, Pomper MG, Gorin M. Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28887401 DOI: 10.2967/Jnumed.117.195255 |
0.393 |
|
| 2017 |
Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, Allaf ME, Pienta KJ, Lapa C, Buck AK, Higuchi T, Pomper MG, Gorin MA, Rowe SP. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine. PMID 28831739 DOI: 10.1007/S12149-017-1201-4 |
0.423 |
|
| 2017 |
Turkbey B, Mena E, Lindenberg L, Adler S, Bednarova S, Berman R, Ton AT, McKinney Y, Eclarinal P, Hill C, Afari G, Bhattacharyya S, Mease RC, Merino MJ, Jacobs PM, ... ... Pomper MG, et al. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology. Clinical Nuclear Medicine. PMID 28806263 DOI: 10.1097/Rlu.0000000000001804 |
0.441 |
|
| 2017 |
Rowe SP, Gorin MA, Chu LC, Pienta KJ, Pomper MG, Ross AE, Macura KJ. An Unusual Case of Penile Prostate Cancer Uncovered by Multiparametric MRI and PSMA-Targeted 18F-DCFPyL PET/CT. Clinical Nuclear Medicine. PMID 28806262 DOI: 10.1097/Rlu.0000000000001785 |
0.444 |
|
| 2017 |
Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, Pienta KJ, Allaf ME, Haberkorn U, Pomper MG, Gorin MA, Rowe SP. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. PMID 28765998 DOI: 10.1007/S00259-017-3780-7 |
0.468 |
|
| 2017 |
Salas Fragomeni RA, Menke JR, Holdhoff M, Ferrigno C, Laterra JJ, Solnes LB, Javadi MS, Szabo Z, Pomper MG, Rowe SP. Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas. Clinical Nuclear Medicine. PMID 28737579 DOI: 10.1097/Rlu.0000000000001769 |
0.451 |
|
| 2017 |
Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, et al. PSMA-targeted (18)F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study. The Journal of Urology. PMID 28736318 DOI: 10.1016/J.Juro.2017.07.070 |
0.394 |
|
| 2017 |
Gorin MA, Pomper MG, Pienta KJ, Rowe SP. Defining the clinical utility of PSMA-targeted PET imaging of prostate cancer. Bju International. 120: 160-161. PMID 28719112 DOI: 10.1111/Bju.13801 |
0.457 |
|
| 2017 |
Gorin MA, Mareshdeh W, Ross AE, Allaf ME, Pienta KJ, Pomper MG, Rowe SP. Uptake of the prostate-specific membrane antigen-targeted PET radiotracer 18F-DCFPyL in elastofibroma dorsi. Nuclear Medicine Communications. PMID 28704341 DOI: 10.1097/Mnm.0000000000000716 |
0.463 |
|
| 2017 |
Schwarzenböck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Afshar-Oromieh A, Herrmann K, Eiber M. PSMA Ligands for PET-Imaging of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28687599 DOI: 10.2967/Jnumed.117.191031 |
0.473 |
|
| 2017 |
Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, ... Pomper MG, et al. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). Bmc Cancer. 17: 453. PMID 28662647 DOI: 10.1186/s12885-017-3455-6 |
0.42 |
|
| 2017 |
Gorin MA, Pienta KJ, Pomper MG, Rowe SP. Prostate Cancer Local Recurrence Detected with Both (18)F-Fluciclovine and PSMA-Targeted (18)F-DCFPyL PET/CT. Urology. PMID 28641974 DOI: 10.1016/J.Urology.2017.06.015 |
0.432 |
|
| 2017 |
Lee S, Yoon HI, Na JH, Jeon S, Lim S, Koo H, Han SS, Kang SW, Park SJ, Moon SH, Park JH, Cho YW, Kim BS, Kim SK, Lee T, ... ... Pomper MG, et al. In vivo stem cell tracking with imageable nanoparticles that bind bioorthogonal chemical receptors on the stem cell surface. Biomaterials. 139: 12-29. PMID 28582715 DOI: 10.1016/J.Biomaterials.2017.05.050 |
0.313 |
|
| 2017 |
Rowe SP, Gorin MA, Pomper MG. Imaging of Prostate-Specific Membrane Antigen Using [(18)F]DCFPyL. Pet Clinics. 12: 289-296. PMID 28576167 DOI: 10.1016/J.Cpet.2017.02.006 |
0.463 |
|
| 2017 |
Foss CA, Liu L, Mease RC, Wang H, Pasricha P, Pomper MG. Imaging Macrophage Accumulation in a Murine Model of Chronic Pancreatitis with [(125)I]iodoDPA SPECT-CT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28522739 DOI: 10.2967/Jnumed.117.189571 |
0.355 |
|
| 2017 |
Zlitni A, Yin M, Janzen N, Chatterjee S, Lisok A, Gabrielson KL, Nimmagadda S, Pomper MG, Foster FS, Valliant JF. Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. Plos One. 12: e0176958. PMID 28472168 DOI: 10.1371/Journal.Pone.0176958 |
0.385 |
|
| 2017 |
Rowe SP, Gorin MA, Salas Fragomeni RA, Drzezga A, Pomper MG. Clinical Experience with (18)F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen. Pet Clinics. 12: 235-241. PMID 28267456 DOI: 10.1016/J.Cpet.2016.12.006 |
0.442 |
|
| 2017 |
Nováková Z, Foss CA, Copeland BT, Morath V, Baranová P, Havlínová B, Skerra A, Pomper MG, Barinka C. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools. The Prostate. PMID 28247415 DOI: 10.1002/Pros.23311 |
0.391 |
|
| 2017 |
Notter T, Coughlin JM, Gschwind T, Weber-Stadlbauer U, Wang Y, Kassiou M, Vernon AC, Benke D, Pomper MG, Sawa A, Meyer U. Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Molecular Psychiatry. PMID 28093569 DOI: 10.1038/Mp.2016.248 |
0.323 |
|
| 2017 |
Fakhrejahani F, Lindenberg ML, Bargvall ES, Mena E, Turkbey B, Adler S, Gulley JL, Madan RA, Pomper MG, Dahut WL, Choyke PL. Imaging metastatic prostate cancer with 18F-DCFBC PET/CT (DCFBC) and 18F-NaF PET/CT (NaF). Journal of Clinical Oncology. 35: 231-231. DOI: 10.1200/Jco.2017.35.6_Suppl.231 |
0.437 |
|
| 2017 |
Phillips R, Gorin M, Rowe S, Hayman J, Radwan N, Pomper M, Allaf M, Eisenberger M, Ross A, Pienta K, DeWeese T, Greco S, Song D, Deville C, Tran P. Changes in Radiotherapeutic Management of Prostate Cancer Following PSMA-based 18 F-DCFPyL PET Imaging: A Snapshot of Prospective Trials at a Single Institution International Journal of Radiation Oncology*Biology*Physics. 99: E259-E260. DOI: 10.1016/J.Ijrobp.2017.06.1224 |
0.308 |
|
| 2016 |
Li M, Banerjee SR, Zheng C, Pomper MG, Barman I. Ultrahigh affinity Raman probe for targeted live cell imaging of prostate cancer. Chemical Science. 7: 6779-6785. PMID 28451123 DOI: 10.1039/C6Sc01739H |
0.459 |
|
| 2016 |
Chen Y, Chatterjee S, Lisok A, Minn I, Pullambhatla M, Wharram B, Wang Y, Jin J, Bhujwalla ZM, Nimmagadda S, Mease RC, Pomper MG. A PSMA-targeted theranostic agent for photodynamic therapy. Journal of Photochemistry and Photobiology. B, Biology. 167: 111-116. PMID 28063300 DOI: 10.1016/J.Jphotobiol.2016.12.018 |
0.442 |
|
| 2016 |
Chatterjee S, Lesniak WG, Miller MS, Lisok A, Sikorska E, Wharram B, Kumar D, Gabrielson M, Pomper MG, Gabelli SB, Nimmagadda S. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochemical and Biophysical Research Communications. PMID 28025143 DOI: 10.1016/J.Bbrc.2016.12.156 |
0.333 |
|
| 2016 |
Tamborini L, Chen Y, Foss CA, Pinto A, Horti AG, Traynelis SF, De Micheli C, Mease RC, Hansen KB, Conti P, Pomper MG. Development of Radiolabeled Ligands Targeting the Glutamate Binding Site of the N-Methyl-d-aspartate Receptor as Potential Imaging Agents for Brain. Journal of Medicinal Chemistry. 59: 11110-11119. PMID 28002957 DOI: 10.1021/Acs.Jmedchem.6B01344 |
0.317 |
|
| 2016 |
Banerjee SR, Foss CA, Horhota A, Pullambhatla M, McDonnell K, Zale S, Pomper MG. (111)In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues. Biomacromolecules. PMID 28001364 DOI: 10.1021/Acs.Biomac.6B01485 |
0.371 |
|
| 2016 |
Li X, Rowe SP, Leal JP, Gorin MA, Allaf ME, Ross AE, Pienta KJ, Lodge MA, Pomper MG. Quantitative Parameters in PSMA-targeted PET Imaging with 18F-DCFPyL: Variability in Normal Organ Uptake. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27932557 DOI: 10.2967/Jnumed.116.179739 |
0.447 |
|
| 2016 |
Shim MK, Yoon HY, Ryu JH, Koo H, Lee S, Park JH, Kim JH, Lee S, Pomper MG, Kwon IC, Kim K. Cathepsin B-Specific Metabolic Precursor for In Vivo Tumor-Specific Fluorescence Imaging. Angewandte Chemie (International Ed. in English). PMID 27762044 DOI: 10.1002/Anie.201608504 |
0.346 |
|
| 2016 |
Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, Pomper MG, Lotan TL, Ross AE. Correlation of PSMA-Targeted (18)F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. PMID 27751686 DOI: 10.1016/J.Clgc.2016.09.002 |
0.399 |
|
| 2016 |
Rowe SP, Drzezga A, Neumaier B, Dietlein M, Gorin MA, Zalutsky MR, Pomper MG. Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 57: 90S-96S. PMID 27694179 DOI: 10.2967/Jnumed.115.170175 |
0.471 |
|
| 2016 |
Menezes ME, Das SK, Minn I, Emdad L, Wang XY, Sarkar D, Pomper MG, Fisher PB. Detecting Tumor Metastases: The Road to Therapy Starts Here. Advances in Cancer Research. 132: 1-44. PMID 27613128 DOI: 10.1016/Bs.Acr.2016.07.001 |
0.325 |
|
| 2016 |
He QL, Minn I, Wang Q, Xu P, Head SA, Datan E, Yu B, Pomper MG, Liu JO. Targeted Delivery and Sustained Antitumor Activity of Triptolide through Glucose Conjugation. Angewandte Chemie (International Ed. in English). PMID 27574181 DOI: 10.1002/Anie.201606121 |
0.78 |
|
| 2016 |
Kuwabara H, Gao Y, Stabin M, Coughlin J, Nimmagadda S, Dannals RF, Pomper MG, Horti AG. Imaging α4β2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [(18)F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 27562686 DOI: 10.1007/S11307-016-0999-9 |
0.322 |
|
| 2016 |
Moldovan RP, Teodoro R, Gao Y, Deuther-Conrad W, Kranz M, Wang Y, Kuwabara H, Nakano M, Valentine H, Fischer S, Pomper MG, Wong DF, Dannals RF, Brust P, Horti AG. Development of a high affinity PET radioligand for imaging cannabinoid subtype 2 receptor (CB2). Journal of Medicinal Chemistry. PMID 27500461 DOI: 10.1021/Acs.Jmedchem.6B00554 |
0.335 |
|
| 2016 |
Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE. Development and application of a novel model system to study 'active' and 'passive' tumor targeting. Molecular Cancer Therapeutics. PMID 27486224 DOI: 10.1158/1535-7163.Mct-16-0051 |
0.344 |
|
| 2016 |
Airan RD, Foss CA, Ellens NP, Wang Y, Mease RC, Farahani K, Pomper MG. MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 27481359 DOI: 10.1007/S11307-016-0985-2 |
0.361 |
|
| 2016 |
Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn HH, Wang Y, Banerjee SR, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, et al. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget. PMID 27437764 DOI: 10.18632/Oncotarget.10602 |
0.367 |
|
| 2016 |
Gorin MA, Rowe SP, Hooper JE, Kates M, Hammers HJ, Szabo Z, Pomper MG, Allaf ME. PSMA-Targeted (18)F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. European Urology. PMID 27363386 DOI: 10.1016/J.Eururo.2016.06.019 |
0.35 |
|
| 2016 |
Chen Y, Lisok A, Chatterjee S, Wharram B, Pullambhatla M, Wang Y, Sgouros G, Mease RC, Pomper MG. A [18F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance. Bioconjugate Chemistry. PMID 27270097 DOI: 10.1021/Acs.Bioconjchem.6B00195 |
0.456 |
|
| 2016 |
Kiess A, Minn IL, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel M, Mease RC, Sgouros G, Zalutsky MR, ... Pomper M, et al. (2S)-2-(3-(1-Carboxy-5-(4-[211At]astatobenzamido)pentyl)ureido)-pentanedioic acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27230930 DOI: 10.2967/Jnumed.116.174300 |
0.371 |
|
| 2016 |
Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer and Prostatic Diseases. PMID 27136743 DOI: 10.1038/Pcan.2016.13 |
0.46 |
|
| 2016 |
Subedi M, Minn I, Chen J, Kim Y, Ok K, Jung YW, Pomper MG, Byun Y. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands. European Journal of Medicinal Chemistry. 118: 208-218. PMID 27128184 DOI: 10.1016/J.Ejmech.2016.04.033 |
0.409 |
|
| 2016 |
Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 27080322 DOI: 10.1007/S11307-016-0957-6 |
0.459 |
|
| 2016 |
Gorin MA, Pomper MG, Rowe SP. PSMA-targeted imaging of prostate cancer: the best is yet to come. Bju International. 117: 715-6. PMID 27079480 DOI: 10.1111/Bju.13435 |
0.432 |
|
| 2016 |
Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, Pomper MG. A Preclinical Comparative Study of 68Ga-labeled DOTA, NOTA and HBED-CC Chelated Radiotracers for Targeting PSMA. Bioconjugate Chemistry. PMID 27076393 DOI: 10.1021/Acs.Bioconjchem.5B00679 |
0.399 |
|
| 2016 |
Behnam Azad B, Lisok A, Chatterjee S, Poirier JT, Pullambhatla M, Luker GD, Pomper MG, Nimmagadda S. Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26912435 DOI: 10.2967/Jnumed.115.167932 |
0.391 |
|
| 2016 |
Lesniak W, Oskolkov N, Song X, Lal B, Yang X, Pomper MG, Laterra J, Nimmagadda S, McMahon MT. Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. Nano Letters. PMID 26910126 DOI: 10.1021/Acs.Nanolett.5B04517 |
0.319 |
|
| 2016 |
Azad BB, Chatterjee S, Lesniak WG, Lisok A, Pullambhatla M, Bhujwalla ZM, Pomper MG, Nimmagadda S. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget. PMID 26848769 DOI: 10.18632/Oncotarget.7111 |
0.416 |
|
| 2016 |
Gorin MA, Rowe SP, Mana-ay M, Szabo Z, Schaeffer EM, Tran PT, Allaf ME, Deville C, Cho SY, Pienta KJ, Pomper MG, Ross A. Study of PSMA-targeted 18F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy. Journal of Clinical Oncology. 34: 299-299. DOI: 10.1200/Jco.2016.34.2_Suppl.299 |
0.413 |
|
| 2016 |
Minn I, Koo SM, Lee HS, Brummet M, Rowe SP, Gorin MA, Sysa-Shah P, Lewis WD, Ahn H, Wang Y, Ray S, Mease RC, Nimmagadda S, Allaf ME, Pomper MG, et al. Abstract 4206: A dual-motif CAIX inhibitor, [64Cu]XYIMSR-06, for PET imaging of clear cell renal cell carcinoma Cancer Research. 76: 4206-4206. DOI: 10.1158/1538-7445.Am2016-4206 |
0.385 |
|
| 2016 |
Asbrock N, Chu V, Pomper M. Abstract 2508: A red-shifted fluorescent substrate for aldehyde dehydrogenase, AldeRed 588-A, for labeling viable ALDH-positive cells Cancer Research. 76: 2508-2508. DOI: 10.1158/1538-7445.Am2016-2508 |
0.313 |
|
| 2016 |
Gorin MA, Rowe SP, Mana-ay M, Szabo Z, Schaeffer EM, Tran PT, Allaf ME, Deville C, Bivalacqua TJ, Cho SY, Pomper MG, Ross AE. MP50-18 STUDY OF PSMA-TARGETED
18
F-DCFPYL PET/CT IN THE EVALUATION OF MEN WITH AN ELEVATED PSA FOLLOWING RADICAL PROSTATECTOMY Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.452 |
0.35 |
|
| 2016 |
Gorin MA, Rowe SP, Hooper JE, Hammers H, Kates M, Javadi MS, Hawasli H, Szabo Z, Pomper MG, Allaf ME. MP03-10 PILOT STUDY EVALUATING PSMA-TARGETED
18
F-DCFPYL PET/CT IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1903 |
0.318 |
|
| 2016 |
Hobbs RF, Josefsson A, Kiess A, Minn I, Mease R, Brummet M, Vaidyanathan G, Zalutsky M, Pomper M. Application of Small-Scale (Sub-Organ and Cellular Level) Alpha-Particle Specific Dosimetry Model in Tumors and Kidneys in a Pre-Clinical Model of Metastatic Prostate Cancer Using 211At-YC-I-27, a PSMA-Targeting Ligand for Metastatic Prostate Cancer Brachytherapy. 15: S196. DOI: 10.1016/J.Brachy.2016.04.359 |
0.39 |
|
| 2015 |
Rowe SP, Deville C, Paller C, Cho SY, Fishman EK, Pomper MG, Ross AE, Gorin MA. Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. Tomography : a Journal For Imaging Research. 1: 81-84. PMID 26807444 DOI: 10.18383/j.tom.2015.00169 |
0.321 |
|
| 2015 |
Chen Z, Penet MF, Krishnamachary B, Banerjee SR, Pomper MG, Bhujwalla ZM. PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer. Biomaterials. 80: 57-67. PMID 26706476 DOI: 10.1016/J.Biomaterials.2015.11.048 |
0.438 |
|
| 2015 |
Yang X, Mease RC, Pullambhatla M, Lisok A, Foss C, Wang Y, Shallal H, Edelman H, Hoye AT, Attardo G, Nimmagadda S, Pomper MG. [18F]Fluorobenzoyl-Lysine-Pentanedioic Acid Carbamates: New Scaffolds for PET Imaging of PSMA. Journal of Medicinal Chemistry. PMID 26629713 DOI: 10.1021/Acs.Jmedchem.5B01268 |
0.416 |
|
| 2015 |
Rowe SP, Mana-Ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, Pienta KJ, Ross AE, Gorin MA. PSMA-Based Detection of Prostate Cancer Bone Lesions With (18)F-DCFPyL PET/CT: A Sensitive Alternative to (99m)Tc-MDP Bone Scan and Na(18)F PET/CT? Clinical Genitourinary Cancer. PMID 26603549 DOI: 10.1016/J.Clgc.2015.09.011 |
0.423 |
|
| 2015 |
Zhu C, Bandekar A, Sempkowski M, Ray Banerjee S, Pomper MG, Bruchertseifer F, Morgenstern A, Sofou S. Nanoconjugation of PSMA-targeting ligands enhances perinuclear localization and improves efficacy of delivered alpha-particle emitters against tumor endothelial analogues. Molecular Cancer Therapeutics. PMID 26586724 DOI: 10.1158/1535-7163.Mct-15-0207 |
0.33 |
|
| 2015 |
Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA. Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. The Prostate. PMID 26499105 DOI: 10.1002/Pros.23115 |
0.733 |
|
| 2015 |
Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E, Eisenberger M, Carducci M, Ross A, Kantoff P, Holt DP, Dannals RF, Mease RC, Pomper MG, et al. Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26493203 DOI: 10.2967/Jnumed.115.163782 |
0.439 |
|
| 2015 |
Meng J, Liu Y, Gao S, Lin S, Gu X, Pomper MG, Wang PC, Shan L. A Bivalent Recombinant Immunotoxin with High Potency against Tumors with EGFR and EGFRvIII Expression. Cancer Biology & Therapy. 0. PMID 26467217 DOI: 10.1080/15384047.2015.1095403 |
0.32 |
|
| 2015 |
Yang X, Minn I, Rowe SP, Banerjee SR, Gorin MA, Brummet M, Lee HS, Koo SM, Sysa-Shah P, Mease RC, Nimmagadda S, Allaf ME, Pomper MG. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget. PMID 26418876 DOI: 10.18632/Oncotarget.5254 |
0.361 |
|
| 2015 |
Rowe SP, Gorin MA, Hammers HJ, Pomper MG, Allaf ME, Javadi MS. Detection of 18F-FDG PET/CT Occult Lesions with 18F-DCFPyL PET/CT in a Patient with Metastatic Renal Cell Carcinoma. Clinical Nuclear Medicine. PMID 26402128 DOI: 10.1097/Rlu.0000000000000995 |
0.382 |
|
| 2015 |
Oh Y, Swierczewska M, Kim TH, Lim SM, Eom HN, Park JH, Na DH, Kim K, Lee KC, Pomper MG, Lee S. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26381901 DOI: 10.1016/J.Jconrel.2015.09.014 |
0.321 |
|
| 2015 |
Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (18)F-DCFPyL PET/CT. Annals of Nuclear Medicine. PMID 26286635 DOI: 10.1007/S12149-015-1017-Z |
0.383 |
|
| 2015 |
Banerjee SR, Ngen EJ, Rotz MW, Kakkad S, Lisok A, Pracitto R, Pullambhatla M, Chen Z, Shah T, Artemov D, Meade TJ, Bhujwalla ZM, Pomper MG. Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen. Angewandte Chemie (International Ed. in English). PMID 26212031 DOI: 10.1002/Anie.201503417 |
0.442 |
|
| 2015 |
Kiess A, Minn I, Chen Y, Hobbs RF, Sgouros G, Mease RC, Pullambhatla M, Shen C, Foss C, Pomper M. Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26182968 DOI: 10.2967/Jnumed.115.155929 |
0.392 |
|
| 2015 |
Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, ... ... Pomper MG, et al. 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1003-10. PMID 26069305 DOI: 10.2967/Jnumed.115.154336 |
0.443 |
|
| 2015 |
Liu S, Zhang P, Banerjee SR, Xu J, Pomper MG, Cui H. Design and assembly of supramolecular dual-modality nanoprobes. Nanoscale. 7: 9462-6. PMID 25967580 DOI: 10.1039/C5Nr01518A |
0.306 |
|
| 2015 |
Minn I, Bar-Shir A, Yarlagadda K, Bulte JW, Fisher PB, Wang H, Gilad AA, Pomper MG. Tumor-specific expression and detection of a CEST reporter gene. Magnetic Resonance in Medicine. 74: 544-9. PMID 25919119 DOI: 10.1002/Mrm.25748 |
0.333 |
|
| 2015 |
Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, ... Pomper MG, et al. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 17: 565-74. PMID 25896814 DOI: 10.1007/S11307-015-0850-8 |
0.444 |
|
| 2015 |
Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG. Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 628-34. PMID 25722448 DOI: 10.2967/Jnumed.114.149062 |
0.399 |
|
| 2015 |
Behnam Azad B, Banerjee SR, Pullambhatla M, Lacerda S, Foss CA, Wang Y, Ivkov R, Pomper MG. Evaluation of a PSMA-targeted BNF nanoparticle construct. Nanoscale. 7: 4432-42. PMID 25675333 DOI: 10.1039/C4Nr06069E |
0.425 |
|
| 2015 |
Lesniak WG, Sikorska E, Shallal H, Behnam Azad B, Lisok A, Pullambhatla M, Pomper MG, Nimmagadda S. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents. Molecular Pharmaceutics. 12: 941-53. PMID 25590535 DOI: 10.1021/Mp500799Q |
0.391 |
|
| 2015 |
Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 771-80. PMID 25501577 DOI: 10.1158/1078-0432.Ccr-14-0891 |
0.767 |
|
| 2015 |
Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC, Foss CA, Pomper MG, Jain SK. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrobial Agents and Chemotherapy. 59: 642-9. PMID 25403669 DOI: 10.1128/Aac.04180-14 |
0.353 |
|
| 2015 |
Azad BB, Chatterjee S, Lisok A, Pullambhatla M, Lesniak WG, Bhujwalla ZM, Pomper M, Nimmagadda S. Abstract 4557: Assessment of a humanized CXCR4 monoclonal antibody for therapeutic monitoring and intervention in experimental NSCLC and TNBC mouse models Cancer Research. 75: 4557-4557. DOI: 10.1158/1538-7445.Am2015-4557 |
0.385 |
|
| 2015 |
Tavakoli B, Chen Y, Guo X, Kang HJ, Pomper M, Boctor EM. Multispectral photoacoustic decomposition with localized regularization for detecting targeted contrast agent Progress in Biomedical Optics and Imaging - Proceedings of Spie. 9323. DOI: 10.1117/12.2080133 |
0.374 |
|
| 2014 |
Weinstein EA, Ordonez AA, DeMarco VP, Murawski AM, Pokkali S, MacDonald EM, Klunk M, Mease RC, Pomper MG, Jain SK. Imaging Enterobacteriaceae infection in vivo with 18F-fluorodeoxysorbitol positron emission tomography. Science Translational Medicine. 6: 259ra146. PMID 25338757 DOI: 10.1126/Scitranslmed.3009815 |
0.321 |
|
| 2014 |
Pomper MG, Fisher PB. Emerging applications of molecular imaging to oncology. Preface. Advances in Cancer Research. 124: xiii. PMID 25287695 DOI: 10.1016/B978-0-12-411638-2.09985-7 |
0.318 |
|
| 2014 |
Minn I, Menezes ME, Sarkar S, Yarlagadda K, Das SK, Emdad L, Sarkar D, Fisher PB, Pomper MG. Molecular-genetic imaging of cancer. Advances in Cancer Research. 124: 131-69. PMID 25287688 DOI: 10.1016/B978-0-12-411638-2.00004-5 |
0.336 |
|
| 2014 |
Wong DF, Kuwabara H, Pomper M, Holt DP, Brasic JR, George N, Frolov B, Willis W, Gao Y, Valentine H, Nandi A, Gapasin L, Dannals RF, Horti AG. Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. 16: 730-8. PMID 25145965 DOI: 10.1007/S11307-014-0779-3 |
0.331 |
|
| 2014 |
Bhatnagar A, Wang Y, Mease RC, Gabrielson M, Sysa P, Minn I, Green G, Simmons B, Gabrielson K, Sarkar S, Fisher PB, Pomper MG. AEG-1 promoter-mediated imaging of prostate cancer. Cancer Research. 74: 5772-81. PMID 25145668 DOI: 10.1158/0008-5472.Can-14-0018 |
0.465 |
|
| 2014 |
Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, G Lesniak W, Mease RC, Pomper MG, Nimmagadda S. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nuclear Medicine and Biology. 41: 552-61. PMID 25038987 DOI: 10.1016/J.Nucmedbio.2014.04.081 |
0.38 |
|
| 2014 |
Pavlicek J, Ptacek J, Cerny J, Byun Y, Skultetyova L, Pomper MG, Lubkowski J, Barinka C. Structural characterization of P1'-diversified urea-based inhibitors of glutamate carboxypeptidase II. Bioorganic & Medicinal Chemistry Letters. 24: 2340-5. PMID 24731280 DOI: 10.1016/J.Bmcl.2014.03.066 |
0.339 |
|
| 2014 |
Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG. Evaluation of prostate-specific membrane antigen as an imaging reporter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 805-11. PMID 24700883 DOI: 10.2967/Jnumed.113.134031 |
0.746 |
|
| 2014 |
Horti AG, Gao Y, Kuwabara H, Wang Y, Abazyan S, Yasuda RP, Tran T, Xiao Y, Sahibzada N, Holt DP, Kellar KJ, Pletnikov MV, Pomper MG, Wong DF, Dannals RF. 18F-ASEM, a radiolabeled antagonist for imaging the α7-nicotinic acetylcholine receptor with PET. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 672-7. PMID 24556591 DOI: 10.2967/Jnumed.113.132068 |
0.329 |
|
| 2014 |
Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, Mease RC, Pomper MG. â¶â´Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. Journal of Medicinal Chemistry. 57: 2657-69. PMID 24533799 DOI: 10.1021/Jm401921J |
0.368 |
|
| 2014 |
Li Y, Foss CA, Pomper MG, Yu SM. Imaging denatured collagen strands in vivo and ex vivo via photo-triggered hybridization of caged collagen mimetic peptides. Journal of Visualized Experiments : Jove. e51052. PMID 24513868 DOI: 10.3791/51052 |
0.308 |
|
| 2014 |
Shallal HM, Minn I, Banerjee SR, Lisok A, Mease RC, Pomper MG. Heterobivalent agents targeting PSMA and integrin-αvβ3. Bioconjugate Chemistry. 25: 393-405. PMID 24410012 DOI: 10.1021/Bc4005377 |
0.422 |
|
| 2014 |
Nimmagadda S, Pullambhatla M, Lisok A, Hu C, Maitra A, Pomper MG. Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochemical and Biophysical Research Communications. 443: 635-40. PMID 24333418 DOI: 10.1016/J.Bbrc.2013.12.014 |
0.41 |
|
| 2014 |
Foss C, Pomper M. Time-resolved near-IR imaging of tumors and macrophages Spie Newsroom. DOI: 10.1117/2.1201404.005428 |
0.323 |
|
| 2014 |
Banerjee SR, Wang B, Pullambhatla M, Foss CA, Pomper MG, Morgan RH. Albumin-based nanoformulation for prostate-specific membrane antigen (PSMA) Nuclear Medicine and Biology. 41: 641-642. DOI: 10.1016/J.Nucmedbio.2014.05.135 |
0.363 |
|
| 2014 |
Khattab M, Raval R, Zhang Y, Regter S, Hedayati M, Banerjee S, Zhou H, Ferraris D, Alt J, Rojas C, Slusher B, Pomper M, DeWeese T. PSMA-Targeted Low Molecular Weight Urea-siRNA Conjugates for Targeted Knockdown of DNA-PK and Radiosensitization of Prostate Cancer Cell Lines International Journal of Radiation Oncology*Biology*Physics. 90: S798-S799. DOI: 10.1016/J.Ijrobp.2014.05.2306 |
0.362 |
|
| 2013 |
Chapman S, Dobrovolskaia M, Farahani K, Goodwin A, Joshi A, Lee H, Meade T, Pomper M, Ptak K, Rao J, Singh R, Sridhar S, Stern S, Wang A, Weaver JB, et al. Nanoparticles for cancer imaging: The good, the bad, and the promise. Nano Today. 8: 454-460. PMID 25419228 DOI: 10.1016/J.Nantod.2013.06.001 |
0.382 |
|
| 2013 |
Byun Y, Pullambhatla M, Wang H, Mease RC, Pomper MG. Synthesis and Biological Evaluation of Substrate-Based Imaging Agents for the Prostate-Specific Membrane Antigen. Macromolecular Research. 21: 565-573. PMID 25328507 DOI: 10.1007/S13233-013-1050-5 |
0.462 |
|
| 2013 |
Kiess AP, Cho SY, Pomper MG. Translational Molecular Imaging of Prostate Cancer. Current Radiology Reports. 1: 216-226. PMID 24159427 DOI: 10.1007/S40134-013-0020-1 |
0.461 |
|
| 2013 |
Franc BL, Cho SY, Rosenthal SA, Cui Y, Tsui B, Vandewalker KM, Holz AL, Poonamallee U, Pomper MG, James RB. Detection and localization of carcinoma within the prostate using high resolution transrectal gamma imaging (TRGI) of monoclonal antibody directed at prostate specific membrane antigen (PSMA)--proof of concept and initial imaging results. European Journal of Radiology. 82: 1877-84. PMID 23993140 DOI: 10.1016/J.Ejrad.2013.07.025 |
0.426 |
|
| 2013 |
Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA). Journal of Medicinal Chemistry. 56: 6108-21. PMID 23799782 DOI: 10.1021/Jm400823W |
0.372 |
|
| 2013 |
Kim TH, Swierczewska M, Oh Y, Kim A, Jo DG, Park JH, Byun Y, Sadegh-Nasseri S, Pomper MG, Lee KC, Lee S. Mix to validate: a facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo. Angewandte Chemie (International Ed. in English). 52: 6880-4. PMID 23740787 DOI: 10.1002/Anie.201302181 |
0.621 |
|
| 2013 |
Mease RC, Foss CA, Pomper MG. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Current Topics in Medicinal Chemistry. 13: 951-62. PMID 23590171 DOI: 10.2174/1568026611313080008 |
0.452 |
|
| 2013 |
Baba JS, Endres CJ, Foss CA, Nimmagadda S, Jung H, Goddard JS, Lee S, McKisson J, Smith MF, Stolin AV, Weisenberger AG, Pomper MG. Molecular imaging of conscious, unrestrained mice with AwakeSPECT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 969-76. PMID 23536223 DOI: 10.2967/Jnumed.112.109090 |
0.319 |
|
| 2013 |
Zhou J, Zhu H, Lim M, Blair L, Quinones-Hinojosa A, Messina SA, Eberhart CG, Pomper MG, Laterra J, Barker PB, van Zijl PC, Blakeley JO. Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. Journal of Magnetic Resonance Imaging : Jmri. 38: 1119-28. PMID 23440878 DOI: 10.1002/Jmri.24067 |
0.327 |
|
| 2013 |
Jaaro-Peled H, Niwa M, Foss CA, Murai R, de Los Reyes S, Kamiya A, Mateo Y, O'Donnell P, Cascella NG, Nabeshima T, Guilarte TR, Pomper MG, Sawa A. Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Human Molecular Genetics. 22: 1574-80. PMID 23314019 DOI: 10.1093/Hmg/Ddt007 |
0.338 |
|
| 2013 |
Bar-Shir A, Liu G, Liang Y, Yadav NN, McMahon MT, Walczak P, Nimmagadda S, Pomper MG, Tallman KA, Greenberg MM, van Zijl PC, Bulte JW, Gilad AA. Transforming thymidine into a magnetic resonance imaging probe for monitoring gene expression. Journal of the American Chemical Society. 135: 1617-24. PMID 23289583 DOI: 10.1021/Ja312353E |
0.334 |
|
| 2013 |
Chang C, Chan A, Lin X, Higuchi T, Terrovitis J, Afzal JM, Rittenbach A, Sun D, Vakrou S, Woldemichael K, O'Rourke B, Wahl R, Pomper M, Tsui B, Abraham MR. Cellular bioenergetics is an important determinant of the molecular imaging signal derived from luciferase and the sodium-iodide symporter. Circulation Research. 112: 441-50. PMID 23255420 DOI: 10.1161/Circresaha.112.273375 |
0.34 |
|
| 2013 |
Chaux A, Eifler J, Karram S, Al-Hussain T, Faraj S, Pomper M, Rodriguez R, Netto GJ. Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: Implications for novel intraoperative PSMA-based fluorescent imaging techniques Urologic Oncology: Seminars and Original Investigations. 31: 572-575. PMID 21640619 DOI: 10.7490/F1000Research.1113190.1 |
0.384 |
|
| 2013 |
Bhatnager A, Gabrielson K, Fisher PB, Pomper MG. Abstract 4535: Molecular-genetic imaging of prostate cancer. Cancer Research. 73: 4535-4535. DOI: 10.1158/1538-7445.Am2013-4535 |
0.467 |
|
| 2013 |
Chen Z, Penet MP, Krishnamachary B, Li C, Winnard PT, Pomper MG, Bhujwalla ZM. Abstract 4345: PSMA-targeted theranostic nanoplex combining TRAIL gene cDNA and prodrug enzyme delivery for prostate cancer treatment. Cancer Research. 73: 4345-4345. DOI: 10.1158/1538-7445.Am2013-4345 |
0.452 |
|
| 2013 |
Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Pomper MG, Rodriguez R. Abstract 3919: A preclinical model of laparoscopy demonstrating the feasibility of detecting PSMA positive cells with a NIR fluorophore (YC-27): implications for strategies to decrease positive margins during prostatectomy. Cancer Research. 73: 3919-3919. DOI: 10.1158/1538-7445.Am2013-3919 |
0.742 |
|
| 2013 |
Neuman B, Eifler J, Castanares M, Chowdhury W, Chen Y, Pomper M, Rodriguez R. 1319 A NEAR-INFRARED IMAGING AGENT IDENTIFIES PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITIVE CELLS DURING LAPAROSCOPIC SURGERY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2673 |
0.74 |
|
| 2013 |
Kim TH, Swierczewska M, Oh Y, Kim A, Jo DG, Park JH, Byun Y, Sadegh-Nasseri S, Pomper MG, Lee KC, Lee S. Rücktitelbild: Mix to Validate: A Facile, Reversible PEGylation for Fast Screening of Potential Therapeutic Proteins In Vivo (Angew. Chem. 27/2013) Angewandte Chemie. 125: 7182-7182. DOI: 10.1002/Ange.201304233 |
0.615 |
|
| 2012 |
Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, ... ... Pomper MG, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1883-91. PMID 23203246 DOI: 10.2967/Jnumed.112.104661 |
0.446 |
|
| 2012 |
Chen Y, Pullambhatla M, Banerjee. SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG. SYnthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen Bioconjugate Chemistry. 23: 2377-2385. PMID 23157641 DOI: 10.1021/Bc3003919 |
0.443 |
|
| 2012 |
Penet MF, Chen Z, Kakkad S, Pomper MG, Bhujwalla ZM. Theranostic imaging of cancer. European Journal of Radiology. 81: S124-6. PMID 23083557 DOI: 10.1016/S0720-048X(12)70051-7 |
0.391 |
|
| 2012 |
Hedvat M, Emdad L, Das SK, Kim K, Dasgupta S, Thomas S, Hu B, Zhu S, Dash R, Quinn BA, Oyesanya RA, Kegelman TP, Sokhi UK, Sarkar S, Erdogan E, ... ... Pomper MG, et al. Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules. Anti-Cancer Agents in Medicinal Chemistry. 12: 1143-55. PMID 22931411 DOI: 10.2174/187152012803529709 |
0.351 |
|
| 2012 |
Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. PSMA-targeted theranostic nanoplex for prostate cancer therapy. Acs Nano. 6: 7752-62. PMID 22866897 DOI: 10.1021/Nn301725W |
0.477 |
|
| 2012 |
Cheng Y, Senthamizhchelvan S, Agarwal R, Green GM, Mease RC, Sgouros G, Huso DL, Pomper MG, Meltzer SJ, Abraham JM. [32P]ATP inhibits the growth of xenografted tumors in nude mice. Cell Cycle (Georgetown, Tex.). 11: 1878-82. PMID 22544324 DOI: 10.4161/Cc.19955 |
0.33 |
|
| 2012 |
Bhang HE, Pomper MG. Cancer imaging: Gene transcription-based imaging and therapeutic systems. The International Journal of Biochemistry & Cell Biology. 44: 684-9. PMID 22349219 DOI: 10.1016/J.Biocel.2012.02.001 |
0.377 |
|
| 2012 |
Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG. GCPII imaging and cancer. Current Medicinal Chemistry. 19: 1346-59. PMID 22304713 DOI: 10.2174/092986712799462612 |
0.457 |
|
| 2012 |
Bařinka C, Rojas C, Slusher B, Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer Current Medicinal Chemistry. 19: 856-870. PMID 22214450 DOI: 10.2174/092986712799034888 |
0.386 |
|
| 2012 |
Sagar D, Foss C, El Baz R, Pomper MG, Khan ZK, Jain P. Mechanisms of dendritic cell trafficking across the blood-brain barrier. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 7: 74-94. PMID 21822588 DOI: 10.1007/S11481-011-9302-7 |
0.301 |
|
| 2012 |
Pomper MG. Abstract IA24: Molecular imaging agents for prostate cancer: Focus on PSMA Cancer Research. 72: IA24-IA24. DOI: 10.1158/1538-7445.Prca2012-Ia24 |
0.439 |
|
| 2012 |
Pomper MG. Abstract SY13-02: In vivo cancer theranostics Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy13-02 |
0.361 |
|
| 2011 |
Banerjee SR, Pullambhatla M, Shallal H, Lisok A, Mease RC, Pomper MG. A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA). Oncotarget. 2: 1244-53. PMID 22207391 DOI: 10.18632/Oncotarget.415 |
0.47 |
|
| 2011 |
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7645-53. PMID 22042970 DOI: 10.1158/1078-0432.Ccr-11-1357 |
0.443 |
|
| 2011 |
Penet MF, Gadiya MM, Krishnamachary B, Nimmagadda S, Pomper MG, Artemov D, Bhujwalla ZM. Metabolic signatures imaged in cancer-induced cachexia. Cancer Research. 71: 6948-56. PMID 21948967 DOI: 10.1158/0008-5472.Can-11-1095 |
0.389 |
|
| 2011 |
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angewandte Chemie (International Ed. in English). 50: 9167-70. PMID 21861274 DOI: 10.1002/Anie.201102872 |
0.465 |
|
| 2011 |
Hobbs RF, Baechler S, Fu DX, Esaias C, Pomper MG, Ambinder RF, Sgouros G. A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. Medical Physics. 38: 2892-903. PMID 21815364 DOI: 10.1118/1.3576051 |
0.308 |
|
| 2011 |
Patil RR, Yu J, Banerjee SR, Ren Y, Leong D, Jiang X, Pomper M, Tsui B, Kraitchman DL, Mao HQ. Probing in vivo trafficking of polymer/DNA micellar nanoparticles using SPECT/CT imaging. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1626-35. PMID 21750533 DOI: 10.1038/Mt.2011.128 |
0.308 |
|
| 2011 |
De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 986-93. PMID 21622896 DOI: 10.2967/Jnumed.110.085613 |
0.382 |
|
| 2011 |
Wilson BA, Wang H, Nacev BA, Mease RC, Liu JO, Pomper MG, Isaacs WB. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S). Molecular Cancer Therapeutics. 10: 825-38. PMID 21441411 DOI: 10.1158/1535-7163.Mct-10-0902 |
0.377 |
|
| 2011 |
Higgins LJ, Pomper MG. The evolution of imaging in cancer: current state and future challenges. Seminars in Oncology. 38: 3-15. PMID 21362512 DOI: 10.1053/J.Seminoncol.2010.11.010 |
0.381 |
|
| 2011 |
Bhang HE, Gabrielson KL, Laterra J, Fisher PB, Pomper MG. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nature Medicine. 17: 123-9. PMID 21151140 DOI: 10.1038/Nm.2269 |
0.368 |
|
| 2011 |
Peterson RA, Gabrielson KL, Allan Johnson G, Pomper MG, Coatney RW, Winkelmann CT. Continuing education course #1: non-invasive imaging as a problem-solving tool and translational biomarker strategy in toxicologic pathology. Toxicologic Pathology. 39: 267-72. PMID 21147931 DOI: 10.1177/0192623310390392 |
0.36 |
|
| 2011 |
Penet M, Winnard PT, Marik R, Nimmagadda S, Pomper MG, Bhujwalla ZM. Abstract 5276: Exploration of the cachectic phenotype Cancer Research. 71: 5276-5276. DOI: 10.1158/1538-7445.Am2011-5276 |
0.379 |
|
| 2011 |
Chen Z, Penet M, Nimmagadda S, Li C, Ray S, Winnard PT, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. Abstract 3629: Theranostic imaging of metastatic prostate cancer Cancer Research. 71: 3629-3629. DOI: 10.1158/1538-7445.Am2011-3629 |
0.455 |
|
| 2011 |
Eifler J, Chowdhury W, Castanares M, Foss C, George N, Pomper M, Rodriguez R. V1221 INTRAOPERATIVE USE OF A PROSTATE SPECIFIC MEMBRANE ANTIGEN-BASED FLUORESCENT IMAGING AGENT FOR PROSTATE CANCER IN A MOUSE MODEL Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.879 |
0.753 |
|
| 2011 |
Eifler J, Chowdhury W, Foss C, Castanares M, Chen Y, George N, Pomper M, Rodriguez R. 1623 A FLUORESCENT IMAGING AGENT SPECIFICALLY TARGET PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CELLS Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1731 |
0.751 |
|
| 2011 |
Rosenberg P, Endres C, Lyketsos C, Coughlin J, Kassiou M, Pomper M. P4-070: Quantifying translocator protein (TSPO) in Alzheimer's disease and cognitively healthy older persons with 11C-DPA-713 PET imaging Alzheimer's & Dementia. 7: S725-S725. DOI: 10.1016/J.Jalz.2011.05.2091 |
0.301 |
|
| 2011 |
Park J, Dvoracek C, Lee KH, Galloway JF, Bhang HC, Pomper MG, Searson PC. Imaging: CuInSe/ZnS Core/Shell NIR Quantum Dots for Biomedical Imaging (Small 22/2011) Small. 7: 3106-3106. DOI: 10.1002/Smll.201190087 |
0.6 |
|
| 2010 |
Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A, Liu JO. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. Journal of the National Cancer Institute. 102: 1855-73. PMID 21088277 DOI: 10.1093/Jnci/Djq457 |
0.307 |
|
| 2010 |
Green MV, Ostrow HG, Seidel J, Pomper MG. Experimental evaluation of depth-of-interaction correction in a small-animal positron emission tomography scanner Molecular Imaging. 9: 311-318. PMID 21084028 DOI: 10.2310/7290.2010.00038 |
0.327 |
|
| 2010 |
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. Journal of Medicinal Chemistry. 53: 5333-41. PMID 20568777 DOI: 10.1021/Jm100623E |
0.429 |
|
| 2010 |
Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Research. 70: 3935-44. PMID 20460522 DOI: 10.1158/0008-5472.Can-09-4396 |
0.408 |
|
| 2010 |
Joyal JL, Barrett JA, Marquis JC, Chen J, Hillier SM, Maresca KP, Boyd M, Gage K, Nimmagadda S, Kronauge JF, Friebe M, Dinkelborg L, Stubbs JB, Stabin MG, Mairs R, ... Pomper MG, et al. Preclinical evaluation of an 131I-labeled benzamide for targeted radiotherapy of metastatic melanoma. Cancer Research. 70: 4045-53. PMID 20442292 DOI: 10.1158/0008-5472.Can-09-4414 |
0.359 |
|
| 2010 |
Wang H, Byun Y, Barinka C, Pullambhatla M, Bhang HE, Fox JJ, Lubkowski J, Mease RC, Pomper MG. Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorganic & Medicinal Chemistry Letters. 20: 392-7. PMID 19897367 DOI: 10.1016/J.Bmcl.2009.10.061 |
0.307 |
|
| 2010 |
Chen Z, Penet M, Nimmagadda S, Li C, Ray S, Winnard PT, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. Abstract 5481: Theranostic imaging of metastatic prostate cancer Cancer Research. 70: 5481-5481. DOI: 10.1158/1538-7445.Am10-5481 |
0.47 |
|
| 2010 |
Penet M, Nimmagadda S, Gadiya M, Krishnamachary B, Pomper MG, Bhujwalla ZM. Abstract 4172: Multi-parametric characterization of an experimental model of cancer cachexia Cancer Research. 70: 4172-4172. DOI: 10.1158/1538-7445.Am10-4172 |
0.418 |
|
| 2009 |
Terrovitis J, Lautamäki R, Bonios M, Fox J, Engles JM, Yu J, Leppo MK, Pomper MG, Wahl RL, Seidel J, Tsui BM, Bengel FM, Abraham MR, Marbán E. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. Journal of the American College of Cardiology. 54: 1619-26. PMID 19833262 DOI: 10.1016/J.Jacc.2009.04.097 |
0.321 |
|
| 2009 |
Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC, Pomper MG. A low molecular weight PSMA-based fluorescent imaging agent for cancer Biochemical and Biophysical Research Communications. 390: 624-629. PMID 19818734 DOI: 10.1016/J.Bbrc.2009.10.017 |
0.455 |
|
| 2009 |
Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrobial Agents and Chemotherapy. 53: 4879-84. PMID 19738022 DOI: 10.1128/Aac.00789-09 |
0.32 |
|
| 2009 |
Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Research. 69: 6932-40. PMID 19706750 DOI: 10.1158/0008-5472.Can-09-1682 |
0.458 |
|
| 2009 |
Wang H, Pullambhatla M, Guilarte TR, Mease RC, Pomper MG. Synthesis of [(125)I]iodoDPA-713: a new probe for imaging inflammation. Biochemical and Biophysical Research Communications. 389: 80-3. PMID 19703411 DOI: 10.1016/J.Bbrc.2009.08.102 |
0.308 |
|
| 2009 |
Zaheer A, Cho SY, Pomper MG. New agents and techniques for imaging prostate cancer Journal of Nuclear Medicine. 50: 1387-1390. PMID 19690043 DOI: 10.2967/Jnumed.109.061838 |
0.435 |
|
| 2009 |
Zhang Y, Byun Y, Ren YR, Liu JO, Laterra J, Pomper MG. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay Cancer Research. 69: 5867-5875. PMID 19567678 DOI: 10.1158/0008-5472.Can-08-4866 |
0.307 |
|
| 2009 |
LeBeau AM, Banerjee SR, Pomper MG, Mease RC, Denmeade SR. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorganic & Medicinal Chemistry. 17: 4888-93. PMID 19541487 DOI: 10.1016/J.Bmc.2009.06.012 |
0.4 |
|
| 2009 |
Nimmagadda S, Glunde K, Pomper MG, Bhujwalla ZM. Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia (New York, N.Y.). 11: 477-84. PMID 19412432 DOI: 10.1593/Neo.81430 |
0.334 |
|
| 2009 |
Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2697-704. PMID 19380450 DOI: 10.1200/Jco.2008.18.8383 |
0.352 |
|
| 2009 |
Pomper MG, Hammond H, Yu X, Ye Z, Foss CA, Lin DD, Fox JJ, Cheng L. Serial imaging of human embryonic stem-cell engraftment and teratoma formation in live mouse models. Cell Research. 19: 370-9. PMID 19114988 DOI: 10.1038/Cr.2008.329 |
0.34 |
|
| 2009 |
Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia (New York, N.Y.). 11: 96-101. PMID 19107236 DOI: 10.1593/Neo.81264 |
0.316 |
|
| 2009 |
Rosenberg PB, Lyketsos CG, Endres C, Hammoud D, Pomper M. P4-172: Pet imaging of translocator protein (TSPO) in elderly controls using [11C]DPA-713 Alzheimer's & Dementia. 5: P482-P482. DOI: 10.1016/J.Jalz.2009.04.739 |
0.33 |
|
| 2008 |
Ma W, Song D, Jacene H, Vilardell F, Zhang X, Messersmith W, Endres C, Jimeno A, Pomper M, Hidalgo M. Changes in FDG-PET in response to rapamycin (R) correlated with Akt pathway inhibition and not with clinical outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3511. PMID 27949750 DOI: 10.1200/Jco.2008.26.15_Suppl.3511 |
0.341 |
|
| 2008 |
Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, Wang Y, Sooryakumar D, Yu SJ, Pomper MG, Tsui BM. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Molecular Imaging. 7: 132-8. PMID 19123983 DOI: 10.2310/7290.2008.00015 |
0.321 |
|
| 2008 |
Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry. 51: 7933-43. PMID 19053825 DOI: 10.1021/Jm801055H |
0.772 |
|
| 2008 |
Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: Structural characterization Journal of Medicinal Chemistry. 51: 7737-7743. PMID 19053759 DOI: 10.1021/Jm800765E |
0.749 |
|
| 2008 |
Terrovitis J, Kwok KF, Lautamäki R, Engles JM, Barth AS, Kizana E, Miake J, Leppo MK, Fox J, Seidel J, Pomper M, Wahl RL, Tsui B, Bengel F, Marbán E, et al. Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography. Journal of the American College of Cardiology. 52: 1652-60. PMID 18992656 DOI: 10.1016/J.Jacc.2008.06.051 |
0.339 |
|
| 2008 |
Fu DX, Foss CA, Nimmagadda S, Ambinder RF, Pomper MG. Imaging virus-associated cancer. Current Pharmaceutical Design. 14: 3048-65. PMID 18991718 DOI: 10.2174/138161208786404371 |
0.383 |
|
| 2008 |
Zhou J, Blakeley JO, Hua J, Kim M, Laterra J, Pomper MG, van Zijl PC. Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 60: 842-9. PMID 18816868 DOI: 10.1002/Mrm.21712 |
0.341 |
|
| 2008 |
Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nature Medicine. 14: 1118-22. PMID 18776891 DOI: 10.1038/Nm.1864 |
0.31 |
|
| 2008 |
Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biology & Therapy. 7: 974-82. PMID 18698158 DOI: 10.4161/Cbt.7.6.5968 |
0.375 |
|
| 2008 |
Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) Journal of Medicinal Chemistry. 51: 4504-4517. PMID 18637669 DOI: 10.1021/Jm800111U |
0.749 |
|
| 2008 |
Winnard PT, Pathak AP, Dhara S, Cho SY, Raman V, Pomper MG. Molecular imaging of metastatic potential. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 96S-112S. PMID 18523068 DOI: 10.2967/Jnumed.107.045948 |
0.374 |
|
| 2008 |
Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG. N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L- cysteine, [18F]DCFBC: A new Imaging probe for prostate cancer Clinical Cancer Research. 14: 3036-3043. PMID 18483369 DOI: 10.1158/1078-0432.Ccr-07-1517 |
0.791 |
|
| 2008 |
Nimmagadda S, Ford EC, Wong JW, Pomper MG. Targeted molecular imaging in oncology: focus on radiation therapy. Seminars in Radiation Oncology. 18: 136-48. PMID 18314068 DOI: 10.1016/J.Semradonc.2007.10.009 |
0.386 |
|
| 2007 |
Diaz LA, Foss CA, Thornton K, Nimmagadda S, Endres CJ, Uzuner O, Seyler TM, Ulrich SD, Conway J, Bettegowda C, Agrawal N, Cheong I, Zhang X, Ladenson PW, Vogelstein BN, ... ... Pomper MG, et al. Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT. Plos One. 2: e1007. PMID 17925855 DOI: 10.1371/Journal.Pone.0001007 |
0.332 |
|
| 2007 |
Zhang Y, Bressler JP, Neal J, Lal B, Bhang HE, Laterra J, Pomper MG. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Research. 67: 9389-97. PMID 17909048 DOI: 10.1158/0008-5472.Can-07-0944 |
0.345 |
|
| 2007 |
Hammoud DA, Hoffman JM, Pomper MG. Molecular neuroimaging: from conventional to emerging techniques. Radiology. 245: 21-42. PMID 17885179 DOI: 10.1148/Radiol.2451060731 |
0.312 |
|
| 2007 |
Madar I, Ravert H, Nelkin B, Abro M, Pomper M, Dannals R, Frost JJ. Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation European Journal of Nuclear Medicine and Molecular Imaging. 34: 2057-2065. PMID 17786439 DOI: 10.1007/S00259-007-0500-8 |
0.303 |
|
| 2007 |
Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomarkers : Section a of Disease Markers. 3: 1-33. PMID 17655039 DOI: 10.3233/Cbm-2007-3101 |
0.316 |
|
| 2007 |
Foss CA, Fox JJ, Feldmann G, Maitra A, Iacobuzio-Donohue C, Kern SE, Hruban R, Pomper MG. Radiolabeled anti-claudin 4 and anti-prostate stem cell antigen: initial imaging in experimental models of pancreatic cancer. Molecular Imaging. 6: 131-9. PMID 17445507 DOI: 10.2310/7290.2007.00010 |
0.394 |
|
| 2007 |
Lee JS, Orita H, Gabrielson K, Alvey S, Hagemann RL, Kuhajda FP, Gabrielson E, Pomper MG. FDG-PET for pharmacodynamic assessment of the fatty acid synthase inhibitor C75 in an experimental model of lung cancer. Pharmaceutical Research. 24: 1202-7. PMID 17404812 DOI: 10.1007/S11095-007-9264-X |
0.355 |
|
| 2007 |
Fu DX, Tanhehco YC, Chen J, Foss CA, Fox JJ, Lemas V, Chong JM, Ambinder RF, Pomper MG. Virus-associated tumor imaging by induction of viral gene expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 1453-8. PMID 17332288 DOI: 10.1158/1078-0432.Ccr-06-2295 |
0.361 |
|
| 2007 |
Fu D, Chong J, Foss C, Fox J, Wang S, Green G, Chen J, Lemas MV, Pomper M, Ambinder R. Imaging and therapy for Epstein-Barr virus-associated gastric cancer Journal of Clinical Oncology. 25: 4644-4644. DOI: 10.1200/Jco.2007.25.18_Suppl.4644 |
0.331 |
|
| 2007 |
Orita H, Coulter J, Tully E, Pinn M, Thupari J, Pomper M, Townsend C, Ettinger D, Kuhajda F, Gabrielson E. Second-generation inhibitors of fatty acid synthase for lung cancer treatment Journal of Clinical Oncology. 25: 18185-18185. DOI: 10.1200/Jco.2007.25.18_Suppl.18185 |
0.304 |
|
| 2007 |
Ma W, Jimeno A, Kulesza P, Chan A, Zhang X, Messersmith WA, Gillison ML, Pomper MG, Forastiere AA, Hidalgo M. Early prediction of anti-epidermal growth factor receptor (EGFR) therapy with 18[F]FDG-PET: A preclinical and clinical correlation Journal of Clinical Oncology. 25: 14064-14064. DOI: 10.1200/Jco.2007.25.18_Suppl.14064 |
0.36 |
|
| 2007 |
Liu Z, Armour E, Ford E, Pomper MG, Wong J. TH-C-L100J-09: Noninvasive Evaluation of Early Radiation-Induced Pulmonary Inflammation Via [11C]-PK11195 Based PET Imaging Medical Physics. 34: 2623-2623. DOI: 10.1118/1.2761647 |
0.334 |
|
| 2006 |
Jones CK, Schlosser MJ, van Zijl PC, Pomper MG, Golay X, Zhou J. Amide proton transfer imaging of human brain tumors at 3T. Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 56: 585-92. PMID 16892186 DOI: 10.1002/Mrm.20989 |
0.327 |
|
| 2006 |
Fu D, Lemas V, Foss C, Fox J, Pomper M, Ambinder RF. Enzymatically-targeted 131I therapy for herpesvirus-associated malignancies Journal of Clinical Oncology. 24: 3010-3010. DOI: 10.1200/Jco.2006.24.18_Suppl.3010 |
0.307 |
|
| 2006 |
Warlick CA, Pomper MG, Isaacs WB, De Marzo AM, Rodriguez R. 1552: Alpha-Methylacyl-COA Racemase (AMACR)-Based Molecular Imaging of Prostate Cancer Journal of Urology. 175: 501-501. DOI: 10.1016/S0022-5347(18)33756-X |
0.389 |
|
| 2006 |
Endres C, Seidel J, Foss C, Fox J, Pomper M. Mouse dosimetry using small animal PET Neuroimage. 31: T57. DOI: 10.1016/J.Neuroimage.2006.04.048 |
0.305 |
|
| 2005 |
Pomper MG. Translational molecular imaging for cancer Cancer Imaging : the Official Publication of the International Cancer Imaging Society. 5. PMID 16361132 DOI: 10.1102/1470-7330.2005.0101 |
0.391 |
|
| 2005 |
Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nature Reviews. Drug Discovery. 4: 1015-26. PMID 16341066 DOI: 10.1038/Nrd1903 |
0.363 |
|
| 2005 |
Pomper MG, Lee JS. Small animal imaging in drug development Current Pharmaceutical Design. 11: 3247-3272. PMID 16250853 DOI: 10.2174/138161205774424681 |
0.343 |
|
| 2005 |
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 4022-8. PMID 15930336 DOI: 10.1158/1078-0432.Ccr-04-2690 |
0.462 |
|
| 2005 |
Li K, Thomasson D, Ketai L, Contag C, Pomper M, Wright M, Bray M. Potential applications of conventional and molecular imaging to biodefense research Clinical Infectious Diseases. 40: 1471-1480. PMID 15844070 DOI: 10.1086/429723 |
0.345 |
|
| 2005 |
Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Brenneman K, Pili R, Pomper M, Carducci MA, Wagner HN. A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chemistry. 16: 43-50. PMID 15656574 DOI: 10.1021/Bc049820H |
0.4 |
|
| 2005 |
Weisenberger AG, Gleason SS, Goddard J, Kross B, Majewski S, Meikle SR, Paulus MJ, Pomper M, Popov V, Smith MF, Welch BL, Wojcik R. A restraint-free small animal SPECT imaging system with motion tracking Ieee Transactions On Nuclear Science. 52: 638-644. DOI: 10.1109/Tns.2005.851399 |
0.302 |
|
| 2004 |
Lin KS, Luu A, Baidoo KE, Hashemzadeh-Gargari H, Chen MK, Pili R, Pomper M, Carducci M, Wagner HN. A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjugate Chemistry. 15: 1416-23. PMID 15546210 DOI: 10.1021/Bc0498267 |
0.374 |
|
| 2004 |
Pomper MG, Hammoud DA. Positron emission tomography in molecular imaging Ieee Engineering in Medicine and Biology Magazine. 23: 28-37. PMID 15508383 DOI: 10.1109/Memb.2004.1337947 |
0.359 |
|
| 2004 |
Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, Tatsumi M, Dang LH, Diaz LA, Pomper M, Abusedera M, Wahl RL, Kinzler KW, Zhou S, Huso DL, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors Proceedings of the National Academy of Sciences of the United States of America. 101: 15172-15177. PMID 15471990 DOI: 10.1073/Pnas.0406242101 |
0.31 |
|
| 2004 |
Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochemical and Biophysical Research Communications. 324: 269-75. PMID 15465013 DOI: 10.1016/J.Bbrc.2004.09.047 |
0.318 |
|
| 2004 |
Scheffel U, Pomper MG. PET imaging of GRP receptor expression in prostate cancer Journal of Nuclear Medicine. 45: 1277-1278. PMID 15299048 |
0.321 |
|
| 2003 |
Wong DF, Pomper MG. Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems Molecular Imaging and Biology. 5: 350-362. PMID 14667490 DOI: 10.1016/J.Mibio.2003.09.011 |
0.338 |
|
| 2003 |
Hammoud DA, Belden CJ, Ho AC, Dal Pan GJ, Herskovits EH, Hilt DC, Brem H, Pomper MG. The surgical bed after BCNU polymer wafer placement for recurrent glioma: Serial assessment on CT and MR imaging American Journal of Roentgenology. 180: 1469-1475. PMID 12704070 DOI: 10.2214/Ajr.180.5.1801469 |
0.317 |
|
| 2003 |
Ouwerkerk R, Bleich KB, Gillen JS, Pomper MG, Bottomley PA. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology. 227: 529-37. PMID 12663825 DOI: 10.1148/Radiol.2272020483 |
0.315 |
|
| 2002 |
Pomper MG, Musachio JL, Zhang J, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP. 11C-MCG: Synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase) Molecular Imaging. 1: 96-101. PMID 12920850 DOI: 10.1162/153535002320162750 |
0.353 |
|
| 2002 |
Pomper MG. Can small animal imaging accelerate drug development? Journal of Cellular Biochemistry. 211-220. PMID 12552620 DOI: 10.1002/Jcb.10443 |
0.345 |
|
| 2002 |
Pomper MG, Constantinides CD, Barker PB, Bizzi A, Dobgan AS, Yokoi F, McArthur JC, Wong DF. Quantitative MR spectroscopic imaging of brain lesions in patients with AIDS: correlation with [11C-methyl]thymidine PET and thallium-201 SPECT. Academic Radiology. 9: 398-409. PMID 11942654 DOI: 10.1016/S1076-6332(03)80185-X |
0.309 |
|
| 2001 |
Pomper MG. Molecular imaging: An overview Academic Radiology. 8: 1141-1153. PMID 11721814 DOI: 10.1016/S1076-6332(03)80728-6 |
0.325 |
|
| 2001 |
Wasserman BA, Stone JH, Hellmann DB, Pomper MG. Original report: Reliability of normal findings on MR imaging for excluding the diagnosis of vasculitis of the central nervous system American Journal of Roentgenology. 177: 455-459. PMID 11461882 DOI: 10.2214/Ajr.177.2.1770455 |
0.338 |
|
| 1992 |
Vanbrocklin HF, Pomper MG, Carlson KE, Welch MJ, Katzenellenbogen JA. Preparation and evaluation of 17-ethynyl-substituted 16α-[18F]fluoroestradiols: Selective receptor-based PET imaging agents Nuclear Medicine and Biology. 19: 363-374. PMID 1629026 DOI: 10.1016/0883-2897(92)90122-F |
0.388 |
|
| 1990 |
Pomper MG, Pinney KG, Carlson KE, van Brocklin H, Mathias CJ, Welch MJ, Katzenellenbogen JA. Target tissue uptake selectivity of three fluorine-substituted progestins: potential imaging agents for receptor-positive breast tumors. International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology. 17: 309-19. PMID 2341287 DOI: 10.1016/0883-2897(90)90058-9 |
0.635 |
|
| 1990 |
Pomper MG, VanBrocklin H, Thieme AM, Thomas RD, Kiesewetter DO, Carlson KE, Mathias CJ, Welch MJ, Katzenellenbogen JA. 11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. Journal of Medicinal Chemistry. 33: 3143-55. PMID 1701833 DOI: 10.1021/Jm00174A009 |
0.33 |
|
| 1988 |
Pomper MG, Katzenellenbogen JA, Welch MJ, Brodack JW, Mathias CJ. 21-[18F]fluoro-16α-ethyl-19-norprogesterone: Synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography Journal of Medicinal Chemistry. 31: 1360-1363. PMID 3260285 DOI: 10.1021/Jm00402A019 |
0.431 |
|
| 1988 |
Carlson KE, Brandes SJ, Pomper MG, Katzenellenbogen JA. Uptake of three [3H]progestins by target tissues in vivo; Implications for the design of diagnostic imaging agents Nuclear Medicine and Biology. 15: 403-408. PMID 3255736 DOI: 10.1016/0883-2897(88)90010-4 |
0.395 |
|
| 1988 |
Carlson KE, Brandes SJ, Pomper MG, Katzenellenbogen JA. Uptake of three [3H]progestins by target tissues in vivo: Implications for the design of diagnostic imaging agents International Journal of Radiation Applications and Instrumentation.. 15: 403-408. DOI: 10.1016/0883-2897(88)90010-4 |
0.395 |
|
| Show low-probability matches. |